US20220087972A9 - Cannabinoid Compositions - Google Patents
Cannabinoid Compositions Download PDFInfo
- Publication number
- US20220087972A9 US20220087972A9 US16/854,800 US202016854800A US2022087972A9 US 20220087972 A9 US20220087972 A9 US 20220087972A9 US 202016854800 A US202016854800 A US 202016854800A US 2022087972 A9 US2022087972 A9 US 2022087972A9
- Authority
- US
- United States
- Prior art keywords
- composition
- sugar
- oil
- thickener
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 125
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 95
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 95
- 235000000346 sugar Nutrition 0.000 claims abstract description 113
- 150000001875 compounds Chemical class 0.000 claims abstract description 58
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 57
- 239000003765 sweetening agent Substances 0.000 claims abstract description 57
- 239000002562 thickening agent Substances 0.000 claims abstract description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 77
- 229960004242 dronabinol Drugs 0.000 claims description 76
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 75
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 52
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 50
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 50
- 229950011318 cannabidiol Drugs 0.000 claims description 50
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 50
- 229920000858 Cyclodextrin Polymers 0.000 claims description 44
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 32
- 239000000230 xanthan gum Substances 0.000 claims description 31
- 229920001285 xanthan gum Polymers 0.000 claims description 31
- 235000010493 xanthan gum Nutrition 0.000 claims description 31
- 229940082509 xanthan gum Drugs 0.000 claims description 31
- 239000007788 liquid Substances 0.000 claims description 28
- 229930006000 Sucrose Natural products 0.000 claims description 21
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical group O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 21
- 244000060011 Cocos nucifera Species 0.000 claims description 17
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 17
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 17
- 229960004793 sucrose Drugs 0.000 claims description 11
- 229930091371 Fructose Natural products 0.000 claims description 10
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 10
- 239000005715 Fructose Substances 0.000 claims description 10
- 235000012907 honey Nutrition 0.000 claims description 10
- 241000208140 Acer Species 0.000 claims description 7
- 241000544066 Stevia Species 0.000 claims 6
- 244000193174 agave Species 0.000 claims 3
- 239000003921 oil Substances 0.000 abstract description 128
- 235000020357 syrup Nutrition 0.000 abstract description 8
- 239000006188 syrup Substances 0.000 abstract description 8
- 241000218236 Cannabis Species 0.000 description 130
- 235000019198 oils Nutrition 0.000 description 123
- 239000003995 emulsifying agent Substances 0.000 description 79
- 238000004945 emulsification Methods 0.000 description 56
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 43
- 238000000034 method Methods 0.000 description 33
- 239000000047 product Substances 0.000 description 33
- 239000002199 base oil Substances 0.000 description 29
- 230000000694 effects Effects 0.000 description 26
- 229960001948 caffeine Drugs 0.000 description 22
- 239000000787 lecithin Substances 0.000 description 22
- 235000010445 lecithin Nutrition 0.000 description 22
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 21
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 21
- 230000008569 process Effects 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 19
- 239000003240 coconut oil Substances 0.000 description 19
- 235000019864 coconut oil Nutrition 0.000 description 19
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 18
- 229940067606 lecithin Drugs 0.000 description 18
- 229940065144 cannabinoids Drugs 0.000 description 17
- 239000000126 substance Substances 0.000 description 16
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 15
- 230000037406 food intake Effects 0.000 description 15
- 229920002907 Guar gum Polymers 0.000 description 14
- 239000000665 guar gum Substances 0.000 description 14
- 235000010417 guar gum Nutrition 0.000 description 14
- 229960002154 guar gum Drugs 0.000 description 14
- 244000025254 Cannabis sativa Species 0.000 description 13
- 241000206575 Chondrus crispus Species 0.000 description 13
- 239000008135 aqueous vehicle Substances 0.000 description 13
- 238000000605 extraction Methods 0.000 description 13
- 241000282412 Homo Species 0.000 description 12
- 235000020415 coconut juice Nutrition 0.000 description 12
- 244000228451 Stevia rebaudiana Species 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- 239000003925 fat Substances 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 10
- 229940097362 cyclodextrins Drugs 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 150000008163 sugars Chemical class 0.000 description 8
- 240000004246 Agave americana Species 0.000 description 7
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 235000019219 chocolate Nutrition 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 235000013311 vegetables Nutrition 0.000 description 5
- 235000019489 Almond oil Nutrition 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 235000019487 Hazelnut oil Nutrition 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 235000019482 Palm oil Nutrition 0.000 description 4
- 235000019483 Peanut oil Nutrition 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 235000019486 Sunflower oil Nutrition 0.000 description 4
- 235000019498 Walnut oil Nutrition 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000008168 almond oil Substances 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- -1 aromatic terpenoid Chemical class 0.000 description 4
- 235000021302 avocado oil Nutrition 0.000 description 4
- 239000008163 avocado oil Substances 0.000 description 4
- 239000001273 butane Substances 0.000 description 4
- 239000000828 canola oil Substances 0.000 description 4
- 235000019519 canola oil Nutrition 0.000 description 4
- 235000005687 corn oil Nutrition 0.000 description 4
- 239000002285 corn oil Substances 0.000 description 4
- 235000012343 cottonseed oil Nutrition 0.000 description 4
- 239000002385 cottonseed oil Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 239000010462 extra virgin olive oil Substances 0.000 description 4
- 235000021010 extra-virgin olive oil Nutrition 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 239000008169 grapeseed oil Substances 0.000 description 4
- 239000010468 hazelnut oil Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 235000019488 nut oil Nutrition 0.000 description 4
- 239000010466 nut oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 239000003346 palm kernel oil Substances 0.000 description 4
- 239000002540 palm oil Substances 0.000 description 4
- 239000000312 peanut oil Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000008171 pumpkin seed oil Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 235000005713 safflower oil Nutrition 0.000 description 4
- 239000003813 safflower oil Substances 0.000 description 4
- 235000021003 saturated fats Nutrition 0.000 description 4
- 239000008159 sesame oil Substances 0.000 description 4
- 235000011803 sesame oil Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002600 sunflower oil Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- 239000008170 walnut oil Substances 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 3
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 3
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 3
- 235000011941 Tilia x europaea Nutrition 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002621 endocannabinoid Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000011874 heated mixture Substances 0.000 description 3
- 239000004571 lime Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 2
- 108050007331 Cannabinoid receptor Proteins 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 244000239659 Eucalyptus pulverulenta Species 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101100268917 Oryctolagus cuniculus ACOX2 gene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 244000294611 Punica granatum Species 0.000 description 2
- 235000014360 Punica granatum Nutrition 0.000 description 2
- UCONUSSAWGCZMV-UHFFFAOYSA-N Tetrahydro-cannabinol-carbonsaeure Natural products O1C(C)(C)C2CCC(C)=CC2C2=C1C=C(CCCCC)C(C(O)=O)=C2O UCONUSSAWGCZMV-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229960003453 cannabinol Drugs 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000006114 decarboxylation reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 235000020375 flavoured syrup Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 201000002859 sleep apnea Diseases 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical class OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- KFKSIUOALVIACE-UHFFFAOYSA-N 3-phenylbenzaldehyde Chemical compound O=CC1=CC=CC(C=2C=CC=CC=2)=C1 KFKSIUOALVIACE-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 239000004866 Hashish Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 241000245026 Scoliopus bigelovii Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000589636 Xanthomonas campestris Species 0.000 description 1
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 235000012467 brownies Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229940105039 coconut extract Drugs 0.000 description 1
- 235000020057 cognac Nutrition 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003132 food thickener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002673 intoxicating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000000075 primary alcohol group Chemical group 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000006254 rheological additive Substances 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 125000003198 secondary alcohol group Chemical group 0.000 description 1
- 150000003333 secondary alcohols Chemical group 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000009394 selective breeding Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/32—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
- A23G1/42—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/32—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
- A23G1/48—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L91/00—Compositions of oils, fats or waxes; Compositions of derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Definitions
- Embodiments of the present invention relate to a method of making Cannabis oil hydrophilic using emulsifiers. More particularly, embodiments of the present invention relate to a water-soluble cannabinoid composition, a cannabinoid composition with caffeine emulsification, Cannabis oil infused sweeteners and elixir that may be bio-available, fast acting and highly metabolizable.
- Cannabinoids are chemical compounds found in the Cannabis plant that interact with receptors in the brain and body to create various effects.
- Herbal Cannabis contains over 400 compounds including over 100 cannabinoids, which are aryl-substituted meroterpenes unique to the plant genus Cannabis .
- the pharmacology of most of the cannabinoids is largely unknown but the most potent psychoactive agent, ⁇ 9 -tetrahydrocannabinol ( ⁇ 9 -THC, or THC), has been isolated, synthesized and much studied due to its abundance and psychoactive attributes.
- Other plant cannabinoids include ⁇ 8 -THC, cannabinol and cannabidiol (CBD). These and other cannabinoids have additive, synergistic or antagonistic effects with THC and may modify its actions when herbal Cannabis is smoked.
- cannabinoids include tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabinol (CBN). These structures are shown in FIG. 1 . All cannabinoids derive from cannabigerol-type compounds and differ mainly in the way this precursor is cyclized. The classical cannabinoids are derived from their respective 2-carboxylic acids (2-COOH) by decarboxylation (catalyzed by heat, light, or alkaline conditions).
- THC isolation came from an Israeli chemist by the name of Raphael Mechoulam. In 1964, Mechoulam isolated and synthesized THC from Lebanese hashish, marking the beginning of Cannabis research that would lead to the discovery of many other cannabinoids, cannabinoid receptors throughout the body, and “endocannabinoids”—the THC-like compounds the human body naturally produces to maintain stability and health.
- CBD and THC levels tend to vary among different plants. Marijuana grown for recreational purposes often contains more THC than CBD. However, by using selective breeding techniques, Cannabis breeders can create varieties with high levels of CBD and next to zero levels of THC.
- the endocannabinoid system (or “ECS”), is a group of specialized signaling chemicals, their receptors, and the metabolic enzymes that produce and break them down. These endocannabinoid chemical signals act on some of the same brain and immune cell receptors (CB1 and CB2) that plant cannabinoids like CBD and THC act on.
- THC works by binding to cannabinoid receptors concentrated in the brain and central nervous system to produce psychoactive effects.
- THC elicits strong cerebral euphoria, while CBD lacks psychoactive effects altogether. This basically comes down to the fact that THC activates CB1 receptors in the human brain while CBD does not.
- CBD cannabinoids
- THC cannabinoids
- CBD's subtle effects are primarily felt in pain, inflammation, and anxiety relief, as well as other medicinal benefits.
- CBD also does not have any adverse side effects that may occur with consumption of THC.
- CBD also does not cause a high. This makes CBD a significant advantage as a medicine, since health professionals prefer treatments with minimal side effects.
- CBD also appears to counteract the sleep-inducing effects of THC, which may explain why some strains of Cannabis are known to increase alertness.
- CBD also acts to reduce the intoxicating effects of THC, such as memory impairment and paranoia.
- THC has a wide range of short-term effects which may or may not be experienced depending on the individual and their body chemistry.
- Some positive short-term effects of THC include: elation, relaxation, sedation, pain relief, energy, hunger, drowsiness, slowed perception of time and laughter.
- THC Trigger Traumatic Stress Disorder
- neuropathic and chronic pain insomnia
- nausea inflammation
- arthritis migraines
- Cancer Crohn's disease
- fibromyalgia Alzheimer's disease
- Glaucoma Glaucoma
- ADHD Attention deficit hyperactivity disorder
- sleep apnea sleep apnea and appetite loss.
- THC Decarboxylation of the THC occurs with heating and is the key to enjoying THC, whether it is consumed by smoking or ingesting.
- Cannabis In its raw form, Cannabis is non-psychoactive, with its primary cannabinoid being THCA.
- THCA cannabinoid
- the invention method provides an advantageous alternative to smoking Cannabis by providing a water-soluble cannabinoid composition for oral ingestion that is bioavailable, highly metabolizable and fast acting.
- THC As an aromatic terpenoid, THC has a very low solubility in water, but good solubility in most organic solvents, specifically lipids and alcohols.
- the problem with edible Cannabis products is they take a varied amount of time to take effect due to the liver's varied ability to process the THC molecule. Depending on liver function at the time, between 2-6% of the THC is able to be metabolized. This process makes it so the THC is absorbed in the esophagus and soft tissues, making it faster acting and more highly metabolizable.
- one or more purposes of embodiments of the present invention is to provide a water-soluble cannabinoid composition, and/or a cannabinoid emulsification (with or without caffeine), and/or Cannabis infused sweeteners and Cannabis infused elixirs to create Cannabis oil infused products for medical and recreational use that are bioavailable, fast acting and highly metabolized, with consistent results that take place in a consistent amount of time.
- elixirs are healing botanicals known to address specific imbalances yet, they are not necessarily teaching the body to mimic the healing chemistry in order for the body to continue healing.
- elixirs are made with delicious flavoring agents, flowers and healthy sweeteners, as well as use a different ratio of medicinal potency. Elixirs are usually a 1:3 or 1:4 in liquid to herb extraction.
- a method to make Cannabis oil water-soluble which uses a combination of emulsifiers and variations in time and temperature of the reaction steps.
- the process results in a Cannabis infused sweeteners and elixirs which provide fast acting, bioavailability and highly metabolizable delivery of the Cannabis oil, either alone or in combination with other edible products.
- Another purpose of the invention is to provide a line of Cannabis oil infused sugars and elixirs that share a base of coconut water infused with coconut fat and to sell the products to wholesale distributors for retail sale in legal dispensaries.
- a purpose of an embodiment of the invention is to provide a method to make Cannabis oil water-soluble using a combination of emulsifiers and variations in time and temperature of the reaction steps.
- One result of the process is a water-soluble, hydrophilic cannabinoid composition, and/or a cannabinoid emulsification and/or Cannabis infused sweeteners and Cannabis infused elixirs which can be used in a variety of edible products providing fast acting, bioavailability and highly metabolizable delivery of the Cannabis oil.
- Another purpose of the invention is to provide a line of Cannabis oil and caffeine edible products that share a base of coconut water infused with coconut fat and to sell the products to wholesale distributors for retail sale in legal dispensaries.
- Another purpose of the invention is to provide a line of Cannabis oil and caffeine infused sugars and elixirs that share a base of coconut water infused with coconut fat and to sell the products to wholesale distributors for retail sale in legal dispensaries.
- a purpose of the invention is to use the water-soluble cannabinoid composition, and/or a cannabinoid emulsification and/or a Cannabis infused sweeteners and elixirs to treat Post Traumatic Stress Disorder, neuropathic and chronic pain, insomnia, nausea, inflammation, arthritis, migraines, Cancer, Crohn's disease, fibromyalgia, Alzheimer's disease, Multiple sclerosis, Glaucoma, Attention deficit hyperactivity disorder (“ADHD”), sleep apnea and appetite loss.
- Post Traumatic Stress Disorder neuropathic and chronic pain
- insomnia nausea, inflammation, arthritis, migraines, Cancer, Crohn's disease, fibromyalgia, Alzheimer's disease, Multiple sclerosis, Glaucoma
- ADHD Attention deficit hyperactivity disorder
- Yet another purpose of an embodiment of the water-soluble Cannabis oil composition, and/or emulsification, and/or sugars and elixirs is to treat pain, inflammation, and anxiety relief.
- the water-soluble Cannabis oil composition, and/or the emulsification, and/or the sugars and elixirs can be combined with chocolate and/or liquor to create edible products.
- compositions can be used to produce other edible products at home or professionally with predictable results, including being fast-acting, and highly metabolizable, which are referred to herein as super-charged.
- This lets consumers know that the invention products have markedly different results than other products.
- These compositions can be marketed in many forms, both in retail and wholesale manufacturing, as well as aiding companies with quality products to use for research and development.
- the above purposes, as well as others which will be apparent, are achieved generally by a method of making Cannabis oil hydrophilic by using a combination of emulsifiers and variations in time and temperature of the reaction steps, and/or cannabinoid emulsification made of at least one emulsifying agent; an aqueous vehicle; a base oil; Cannabis oil; and caffeine, and/or Cannabis infused sweetener comprising Cannabis oil; at least one emulsifying agent selected from the group consisting of xanthan gum, guar gum, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans and a sweetener.
- the resulting cannabinoid emulsification is bio-available, highly metabolizable and fast acting when ingested by the user.
- the specific steps in making the Cannabis oil hydrophilic include first heating a base oil in the range of about 120 to 220° F.
- the Cannabis oil is added to this heated oil (pre heating or post heating) to create a mixture which is then blended at a high speed.
- At least one emulsifying agent is added to the hot mixture while blending is continued. Water is then added to form the composition wherein the Cannabis oil is hydrophilic and is soluble in water.
- This method modifies normally hydrophobic, or “water-repelling”, Cannabis oil into a hydrophilic Cannabis oil alone or when combined with one or more of the following: an emulsification, sweetener/sugar and/or elixir that is bio-available, highly metabolizable and fast acting when ingested by the user.
- the Cannabis oil produced by this method is suitable for use in emulsifications and a component of sugars and elixirs.
- a sweetener used is selected from the group consisting of white sugar, cane sugar, raw sugar, fructose, turbinado sugar, coconut sugar, date sugar, liquid stevia, liquid sugar, powdered sugar, brown sugar, muscovado sugar, honey, agave and other like sweeteners.
- the sweetener component is present in the range of about 98% to about 99.88% of the Cannabis infused sweetener.
- the sweetener is present in the range of about 50%-60%, 60-70%, 70-80%, 80-90% or 90-99.9% for example.
- At least one emulsifying agent is used in the invention process which is selected from the group consisting of xanthan gum, guar gum, cyclodextrin, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans.
- a Cannabis oil is selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoid oils isolated from the marijuana plant.
- THC tetrahydrocannabinol
- CBD cannabidiol
- the Cannabis oil is present in the range of about 1.5 mg to 20 mg per gram of sweetener.
- the emulsifying agent is present in the range of about 0.12% to 2% of the total sweetener.
- the emulsifying agent is a combination of at least two emulsifying agents which can be the same or different.
- the emulsifying agents include cyclodextrin in combination with at least one selected from the group consisting of xanthan gum, guar gum, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans.
- the aqueous vehicle is selected from the group consisting of coconut water, fruit juice, milk and water.
- the aqueous vehicle is in the range of about 60% to 99.9% of the emulsification.
- the preferred vehicle is coconut water.
- the aqueous vehicle is present in the range of about 50%-60%, 60-70%, 70-80%, 80-90% or 90-99.9% for example.
- the base oil is selected from the group consisting of vegetable glycerine, almond oil, avocado oil, canola oil, coconut oil, corn oil, cottonseed oil, grapeseed oil, hazelnut oil, olive oil, extra virgin olive oil, palm oil, peanut oil, palm seed oil, pumpkin seed oil, safflower oil, sesame oil, soy oil, sunflower oil, vegetable oil and walnut oil and any oil high in saturated fats.
- the base oil is preferably in the range of about 0.1% to 40% of the emulsification. Alternatively, the base oil is present in the range of about 0.1%-5%, 5-10%, 10-20%, 20-30% or 30-40% for example.
- the Cannabis oil used in the invention is in a pure state.
- the Cannabis oil used can be extracted from the marijuana plant by CO2 extraction, water extraction, butane extraction and extraction methods that leave a zero testing for residuals.
- the Cannabis oil used in the invention is selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoid oils isolated from the marijuana plant.
- a Cannabis infused elixir comprising Cannabis oil; at least one emulsifying agent; a sweetener selected from the group consisting of white sugar, cane sugar, raw sugar, fructose, turbinado sugar, coconut sugar, date sugar, liquid stevia, liquid sugar, powdered sugar, brown sugar, muscovado sugar, honey, agave and other like sweeteners and flavoring extracts or fruit syrups.
- a sweetener selected from the group consisting of white sugar, cane sugar, raw sugar, fructose, turbinado sugar, coconut sugar, date sugar, liquid stevia, liquid sugar, powdered sugar, brown sugar, muscovado sugar, honey, agave and other like sweeteners and flavoring extracts or fruit syrups.
- the sweetener is present in the range of about 98% to 99.8% of the elixir.
- the Cannabis infused elixir includes Cannabis oil is bio-available, highly metabolizable and fast acting when ingested by the user.
- the Cannabis oil used in the elixir is selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoid oils isolated from the marijuana plant.
- THC tetrahydrocannabinol
- CBD cannabidiol
- the Cannabis oil is present in the range of about 3 mg to 50 mg per ounce of elixir.
- the Cannabis oil and/or elixir is added to the mixture or a drink solution, such as a carbonated or flat water solution, in the range of about 5 mg to 20 mg per 2 ounces of the composition or a ratio between about 1:3 to 1:4 to create a liquid beverage.
- a drink solution such as a carbonated or flat water solution
- the base oil is present in the range of about 0.5 grams to 5 grams of base oil per about 1 ounce of the composition.
- the emulsifying agent is in the range of about 0.15% and about 2% of the total volume of the emulsification and/or the emulsifying agent is present in the range of about 0.15% to about 2% of the elixir.
- the invention also provides a water-soluble cannabinoid composition that is bioavailable, fast acting and highly metabolizable.
- the emulsifying agent is selected from the group consisting of xanthan gum, guar gum, cyclodextrin, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans.
- the base oil in the cannabinoid composition is preferably selected from the group consisting of vegetable glycerine, coconut oil and any oil high in saturated fats.
- other nut oils such as almond oil, avocado oil, canola oil, coconut oil, corn oil, cottonseed oil, grapeseed oil, hazelnut oil, olive oil, extra virgin olive oil, palm oil, peanut oil, palm seed oil, pumpkin seed oil, safflower oil, sesame oil, soy oil, sunflower oil, vegetable oil and walnut oil can be used as the base oil.
- the Cannabis oil in the composition is in a pure state that has been extracted from the marijuana plant by CO2 extraction, water extraction, butane extraction and extraction methods that leave a zero testing for residuals.
- the Cannabis oil in the composition is selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoid oils isolated from the marijuana plant.
- ingredients such as chocolate and liquor can be added to the composition to provide different flavor profiles.
- the emulsifying agent is a combination of at least two emulsifying agents.
- cyclodextrin is used in combination with at least one other emulsifying agent selected from the group consisting of xanthan gum, guar gum, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans.
- the Cannabis oil in the emulsification is in the range of about 5 mg to 30 mg per 2 ounces of the emulsification.
- Caffeine is present in one embodiment of the emulsification in the range of about 10 to 300 mg per 2 ounces of the emulsification.
- the caffeine can be in anhydrous form.
- the base oil to aqueous vehicle ratio is between about 1 to 10 grams of base oil per about 2 ounces of the emulsification.
- the invention also provides a method for making cannabinoid emulsifications comprising the steps of heating a base oil, preferably coconut oil, to between about 120 to 220 degrees F. Adding at least one emulsifying agent, caffeine and Cannabis oil to an aqueous vehicle and adding to the heated coconut oil to create a mixture. Blending the mixture in a high speed machine, while holding the temperature between about 120 to 220 degrees F. to emulsify the mixture and then adding caffeine to the mixture.
- a base oil preferably coconut oil
- the emulsifying agents are added in an amount between 0.15% and 2% of the total volume of the mixture and are selected from the group consisting of xanthan gum, guar gum, cyclodextrin, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans.
- the hot mixture is blended at high speed for between 30 seconds and 2 minutes.
- the resulting cannabinoid emulsification is bio-available, highly metabolizable and fast acting when ingested by the user.
- the emulsifying agent is a combination of at least two emulsifying agents.
- the emulsifying agent is a combination of xanthan gum and cyclodextrin, where the cyclodextrin and xanthan gum are each present in the amount of 0.12 to 2%.
- An embodiment of the present invention is a cannabinoid infused ingestible composition
- a cannabinoid oil comprising a cannabinoid oil; a compound that forms an inclusion complex with the cannabinoid oil; and a thickener; wherein the cannabinoid oil is the only oil in the composition.
- the composition preferably further comprises a sweetener.
- the sweetener is preferably selected from the group consisting of white sugar, cane sugar, raw sugar, fructose, turbinado sugar, coconut sugar, date sugar, stevia, liquid stevia, liquid sugar, powdered sugar, brown sugar, muscovado sugar, maple sugar, honey, and agave.
- the compound preferably comprises cyclodextrin.
- the thickener preferably comprises a gum.
- the gum preferably comprises xanthan gum.
- the cannabinoid preferably comprises tetrahydrocannabinol (THC) and/or cannabidiol (CBD).
- THC tetrahydrocannabinol
- CBD cannabidiol
- the cannabinoid is preferably bio-available, highly metabolizable and fast acting when ingested.
- the compound and the thickener each preferably comprise about 0.12% to 2% of the composition.
- the composition preferably comprises from about 0.01% to 4% of both the compound and the thickener, more preferably from about 0.15% to 3% of both the compound and the thickener.
- the composition preferably comprises equal percentages of the compound and the thickener.
- a cannabinoid infused composition consisting essentially of a cannabinoid oil; an alcohol; water; a compound that forms an inclusion complex with the cannabinoid oil; and a thickener.
- the compound preferably comprises cyclodextrin.
- the thickener preferably comprises a gum.
- the gum preferably comprises xanthan gum.
- the cannabinoid preferably comprises tetrahydrocannabinol (THC) and/or cannabidiol (CBD).
- THC tetrahydrocannabinol
- CBD cannabidiol
- the cannabinoid is preferably bio-available, highly metabolizable and fast acting when ingested.
- the compound and the thickener each comprise 0.12% to 2% of the composition.
- the composition preferably comprises about 0.01% to 4% of both the compound and the thickener, and more preferably about 0.15% to 3% of both the compound and the thickener.
- Another embodiment of the present invention is a cannabinoid infused composition consisting essentially of a cannabinoid oil; water; a compound that forms an inclusion complex with the cannabinoid oil; a thickener; and a sweetener.
- the sweetener is preferably selected from the group consisting of white sugar, cane sugar, raw sugar, fructose, turbinado sugar, coconut sugar, date sugar, stevia, liquid stevia, liquid sugar, powdered sugar, brown sugar, muscovado sugar, maple sugar, honey, and agave.
- the compound preferably comprises cyclodextrin.
- the thickener preferably comprises a gum.
- the gum preferably comprises xanthan gum.
- the cannabinoid preferably comprises tetrahydrocannabinol (THC) and/or cannabidiol (CBD).
- THC tetrahydrocannabinol
- CBD cannabidiol
- the compound and the thickener each preferably comprise about 0.12% to 2% of the composition.
- the composition preferably comprises about 0.01% to 4% of both the compound and the thickener, and more preferably about 0.15% to 3% of both the compound and the thickener.
- the composition preferably comprises equal percentages of the compound and the thickener.
- Another embodiment of the present invention is a cannabinoid infused composition consisting essentially of a cannabinoid oil; a compound that forms an inclusion complex with the cannabinoid oil; a thickener; and a sweetener.
- the sweetener is preferably selected from the group consisting of white sugar, cane sugar, raw sugar, fructose, turbinado sugar, coconut sugar, date sugar, stevia, liquid stevia, liquid sugar, powdered sugar, brown sugar, muscovado sugar, maple sugar, honey, and agave.
- the compound preferably comprises cyclodextrin.
- the thickener preferably comprises a gum.
- the gum preferably comprises xanthan gum.
- the cannabinoid preferably comprises tetrahydrocannabinol (THC) and/or cannabidiol (CBD).
- THC tetrahydrocannabinol
- CBD cannabidiol
- the compound and the thickener each preferably comprise about 0.12% to 2% of the composition.
- the composition preferably comprises about 0.01% to 4% of both the compound and the thickener, and more preferably about 0.15% to 3% of both the compound and the thickener.
- the composition preferably comprises equal percentages of the compound and the thickener.
- FIG. 1 is the formula for THC, cannabinol and cannabidiol and structure
- FIG. 2 is the structure for Xanthan Gum
- FIG. 3 is the structure of Guar Gum.
- FIG. 4 is a chemical structure and the molecular shape of B-cyclodextrin (BCD);
- FIG. 5 is a chemical structure of Lecithin
- FIG. 6 is a chemical structure of Carrageen (kappa).
- FIG. 7 is a chemical structure of a monoglyceride.
- One embodiment of the present invention provides a method of making Cannabis oil hydrophilic.
- the process of the invention modifies normally hydrophobic, or “water-repelling”, Cannabis oil into hydrophilic Cannabis oil that is bio-available, highly metabolizable and fast acting when ingested by the user.
- Another embodiment provides a unique emulsified combination of Cannabis oil, caffeine, and a base oil and aqueous vehicle, which are respectively, preferably coconut oil, and coconut water.
- coconut oil is one of the best sources of excellent fatty acids.
- Emulsified with coconut water, Cannabis oil and caffeine provide a beneficial experience for people experiencing a variety of ailments: insomnia, muscle aches, anxiety, etc., or are in recovery from surgery, or in chemotherapy.
- the emulsification makes the Cannabis oil molecules water-soluble, by modification from its normal hydrophobic state into a hydrophilic (“water-loving”), which makes the Cannabis oil bioavailable, faster acting, and more highly metabolizable.
- Cannabis infused sweetener comprising Cannabis oil; at least one emulsifying agent selected from the group consisting of xanthan gum, guar gum, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans and a sweetener; and Cannabis infused elixir comprising Cannabis oil; at least one emulsifying agent; a sweetener selected from the group consisting of white sugar, cane sugar, raw sugar, fructose, turbinado sugar, coconut sugar, date sugar, liquid stevia, liquid sugar, powdered sugar, brown sugar, muscovado sugar, honey, agave and other like sweeteners and flavoring extracts or fruit syrups.
- a sweetener selected from the group consisting of white sugar, cane sugar, raw sugar, fructose, turbinado sugar, coconut sugar, date sugar, liquid stevia, liquid sugar, powdered sugar, brown sugar, muscova
- both sweetener and elixir embodiments the Cannabis oil therein has been modified from its normal hydrophobic state into a hydrophilic (“water-loving”) state that is bio-available, highly metabolizable and fast acting when ingested by the user.
- Bioavailability refers to the degree to which food nutrients, in this invention, Cannabis oil, are available for absorption and utilization in the body. Bioavailability typically applies to nutrients and drugs which pass through first-pass metabolism, i.e. orally consumed substances. Anything absorbed in the gut first passes through the liver before reaching the rest of the circulation, and both the gut and liver may metabolize it to some extent.
- Metabolizable refers to the process of changing food/substances into a form that can be used by your body.
- the process steps of an embodiment of the invention include first heating a base oil in the range of about 120 to 220° F.
- the Cannabis oil is added to this heated oil to create a mixture which is then blended at a high speed.
- At least one emulsifying agent is added to the hot mixture while blending is continued.
- Water is then added to form the composition wherein the Cannabis oil is hydrophilic and is soluble in water.
- the cannabinoid emulsification embodiment of the invention is made of at least one emulsifying agent; an aqueous vehicle; a base oil; Cannabis oil; and caffeine.
- Emulsions are produced by dispersing normally unmixable material into another by mixing, colloidal milling or homogenization.
- the surface-active qualities of emulsifiers of the invention make them effective emulsifying agents that reduce mixing time and maintain the stability of the dispersion.
- the emulsifying agent in the invention is present in the range of about 0.15% to 2% of the composition.
- At least one emulsifying agent is used in the invention process which is selected from the group consisting of xanthan gum, guar gum, cyclodextrin, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans.
- the emulsifying agent is a combination of at least two different emulsifying agents.
- Cannabis oil including THC and CBD
- THC and CBD are not water-soluble, so it needs to be “trapped” in something with dual polarity—that is, a compound that reconciles the fact that water is polar and the cannabinoid is not.
- the emulsifiers provide this.
- the THC Once trapped in the compound, the THC has new de facto properties, like the ability to dissolve in water, distribute itself evenly, and stay suspended in the solution. It also displays increased bioavailability: while the same amount of Cannabis oil in an edible can take up to two hours to reach the bloodstream, the effects of water-soluble Cannabis oil dissolved in water can be felt more acutely, in as little as 10 minutes.
- cannabinoids are soluble in fat. It is also known that only water-soluble substances can pass the intestine membrane. Fat is itself not water-soluble because it is like cannabinoids, uncharged. Fat absorption into the membrane requires substances with a dipole character to build up vehicles which can connect at the outer surface with water (charged side) and at the inner surface with the fat and the THC (uncharged side).
- Xanthan gum which is also called xanthene, has the chemical formula C 13 H 10 O. Its molecular weight is 182.22 grams/mol.
- FIG. 2 shows the chemical structure of xanthan gum.
- xanthan gum is a substance made by fermenting bacteria with sugars. It is an additive found in both foods and medicines. As a food additive, this substance is utilized either as a thickener or stabilizer. This compound has a variety of uses in medicine, such as in the treatment of diabetes, cholesterol and dry mouth.
- xanthan gum is a polysaccharide secreted by the bacterium Xanthomonas campestris . Its known uses, prior to the invention, is as a food additive and rheology modifier, commonly used as a food thickening agent (in salad dressings, for example) and a stabilizer (in cosmetic products, for example, to prevent ingredients from separating). As seen in FIG. 1 , it is composed of pentasaccharide repeat units, comprising glucose, mannose, and glucuronic acid in the molar ratio 2:2:1. It is produced by the fermentation of glucose, sucrose, or lactose. After a fermentation period, the polysaccharide is precipitated from a growth medium with isopropyl alcohol, dried, and ground into a fine powder. Later, it is added to a liquid medium to form the gum.
- guar gum is a polysaccharide composed of the sugars galactose and mannose.
- FIG. 3 shows that the backbone is a linear chain of ⁇ 1,4-linked mannose residues to which galactose residues are 1,6-linked at every second mannose, forming short side-branches.
- guar gum In water, guar gum is nonionic and hydrocolloidal. It is not affected by ionic strength or pH, but will degrade at extreme pH and temperature (e.g. pH 3 at 50° C.). It remains stable in solution over pH range of about 5-7. Strong acids cause hydrolysis and loss of viscosity, and alkalis in strong concentration also tend to reduce viscosity. It is insoluble in most hydrocarbon solvents. The viscosity attained is dependent on time, temperature, concentration, pH, rate of agitation and practical size of the powdered gum used. The lower the temperature, the lower the rate at which viscosity increases and the lower the final viscosity. Above 80°, the final viscosity is slightly reduced.
- Guar gum has almost eight times the water-thickening potency of cornstarch—only a very small quantity is needed for producing sufficient viscosity.
- it can be used in various multiphase formulations: as an emulsifier because it helps to prevent oil droplets from coalescing, and/or as a stabilizer because it helps to prevent solid particles from settling.
- Cyclodextrins are a group of structurally related natural products formed during bacterial digestion of cellulose. These cyclic oligosaccharides consist of ( ⁇ -1,4)-linked ⁇ -D-glucopyranose units and contain a somewhat lipophilic central cavity and a hydrophilic outer surface. Due to the chair conformation of the glucopyranose units, the cyclodextrins are shaped like a truncated cone rather than perfect cylinders. The hydroxyl functions are oriented to the cone exterior with the primary hydroxyl groups of the sugar residues at the narrow edge of the cone and the secondary hydroxyl groups at the wider edge. The central cavity is lined by the skeletal carbons and ethereal oxygens of the glucose residues, which gives it a lipophilic character. The polarity of the cavity has been estimated to be similar to that of an aqueous ethanolic solution.
- the natural ⁇ -, ⁇ - and ⁇ -cyclodextrin consist of six, seven, and eight glucopyranose units, respectively.
- the natural cyclodextrins, in particular ⁇ CD are of limited aqueous solubility meaning that complexes resulting from interaction of lipophiles with these cyclodextrin can be of limited solubility resulting in precipitation of solid cyclodextrin complexes from water and other aqueous systems.
- the aqueous solubility of the natural cyclodextrins is much lower than that of comparable acyclic saccharides. This is thought to be due to relatively strong intermolecular hydrogen bonding in the crystal state.
- Water-soluble cyclodextrin derivatives of commercial interest include the hydroxypropyl derivatives of ⁇ CD and ⁇ CD, the randomly methylated ⁇ -cyclodextrin (RM ⁇ CD), and sulfobutylether ⁇ -cyclodextrin sodium salt (SBE ⁇ CD).
- FIG. 4 and Table 1 were taken from an article entitled “Cyclodextrins” (A. Magn ⁇ sdóttir, M. Másson and T. Loftsson, J. Incl. Phenom. Macroc. Chem. 44, 213-218, 2002).
- Cyclodextrins create highly concentrated and water-soluble granules. Cyclodextrins are circular structures of sugar molecules that are known to absorb other compounds into their center. They form inclusion complexes with poorly water-soluble compounds. Acting like a molecule magnet, cyclodextrins absorb other molecules and assume their properties. These molecules can absorb up to 60% of their weight in alcohol while remaining in powdered form. It isn't until you mix them with water that they dissolve.
- the emulsifying agent is a combination of at least two different emulsifying agents with at least one being cyclodextrin and the other emulsifying agent selected from the group consisting of xanthan gum, guar gum, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans.
- cyclodextrin is very expensive and some versions even cause unwanted side effects when ingested.
- a lesser amount of cyclodextrin is used in combination with other emulsifiers that are less costly to provide the same or better solubility results. This provides an economic solution to using a lesser amount of cyclodextrin with the benefits at lower cost.
- Lecithins are used in the invention as emulsifiers. They are surface-active; simultaneous hydrophilic (water-loving) and hydrophobic (water-repelling) properties enable lecithins to make stable blends of materials that otherwise do not mix easily and tend to separate.
- Lecithin is a generic term to designate any group of yellow-brownish fatty substances occurring in animal and plant tissues, which are amphiphilic—they attract both water and fatty substances (and so are both hydrophilic and lipophilic). Lecithins are generally used for smoothing food textures, dissolving powders (emulsifying), homogenizing liquid mixtures, and repelling sticking materials. Lecithins are composed of phosphoric acid with choline, glycerol or other fatty acids usually glycolipids or triglyceride. Glycerophospholipids in lecithin include phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, and phosphatidic acid.
- Carrageens are a family of linear sulphated polysaccharides that are extracted from red edible seaweeds. They are widely used in the food industry, for their gelling, thickening, and stabilizing properties. Their main application is in dairy and meat products, due to their strong binding to food proteins. There are three main varieties of carrageenan, which differ in their degree of sulphation. Kappa-carrageenan has one sulphate group per disaccharide, Iota-carrageenan has two, and Lambda-carrageenan has three.
- Monoglycerides are a class of glycerides which are composed of a molecule of glycerol linked to a fatty acid via an ester bond.
- glycerol contains both primary and secondary alcohol groups two different types of monoglycerides may be formed; 1-monoacylglycerols where the fatty acid is attached to a primary alcohol, or a 2-monoacylglycerols where the fatty acid is attached to the secondary alcohol.
- Monoglycerides are primarily used as surfactants, usually in the form of emulsifiers. Together with diglycerides, monoglycerides are commonly added to commercial food products in small quantities which helps to prevent mixtures of oils and water from separating.
- the base oil is present in the range of about 0.5 grams to 5 grams of base oil per 1 ounce of the composition.
- the base oil is preferably in the range of about 0.1% to 40% of the emulsification.
- the base oil is preferably selected from the group consisting of vegetable glycerine, coconut oil and any oil high in saturated fats.
- Nut oils are also used in the invention process.
- the nut oils are selected from the group consisting of almond oil, avocado oil, canola oil, coconut oil, corn oil, cottonseed oil, grapeseed oil, hazelnut oil, olive oil, extra virgin olive oil, palm oil, peanut oil, palm seed oil, pumpkin seed oil, safflower oil, sesame oil, soy oil, sunflower oil, vegetable oil and walnut oil.
- An aqueous vehicle is selected from the group consisting of coconut water, fruit juice, milk and water.
- the aqueous vehicle is in the range of about 60% to 99.9% of the emulsification.
- the preferred vehicle is coconut water.
- the base oil to aqueous vehicle ratio is between about 1 to 10 grams of base oil per 2 ounces of the emulsification.
- the Cannabis oil used in embodiments of the invention is in a pure state. This is important since the intended end use of the products of the invention are to be ingested by humans for medical or recreational use, where permitted.
- the Cannabis oil used can be extracted from the marijuana plant by CO2 extraction, water extraction, butane extraction and extraction methods that leave a zero testing for residuals. Representative structures of the Cannabis oil are illustrated in FIG. 1 .
- the Cannabis oil used in an embodiment of the invention is selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoid oils isolated from the marijuana plant.
- THC tetrahydrocannabinol
- CBD cannabidiol
- other cannabinoid oils isolated from the marijuana plant are selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoid oils isolated from the marijuana plant.
- the Cannabis oil in the emulsification is in the range of about 5 mg to about 30 mg per about 2 ounces of the emulsification.
- the Cannabis oil in the sweetener is present in the range of about 1.5 mg to about 20 mg per gram of sweetener.
- the Cannabis oil present in the elixir is in the range of about 3 mg to about 50 mg per ounce of elixir.
- the Cannabis oil is not completely emulsified. The Cannabis oil remaining un-emulsified is absorbed by the body at a different/longer rate than the emulsified Cannabis oil.
- Caffeine may be present/added in an embodiment of an emulsification in the range of about 10 to about 300 mg per about 2 ounces of the emulsification.
- the caffeine can be in anhydrous form.
- the Cannabis oil is added to the mixture and is present in the range of about 5 mg to 20 mg per about 2 ounces of the composition.
- the sweetener is used in both the infused sweetener and white sugar, cane sugar, raw sugar, fructose, turbinado sugar, coconut sugar, date sugar, liquid stevia, liquid sugar, powdered sugar, brown sugar, muscovado sugar, honey, agave and other like sweeteners.
- the sweetener component is present in the range of about 98% to about 99.88% of the Cannabis infused sweetener or Cannabis infused elixir.
- a water-soluble cannabinoid composition is also provided that is bioavailable, fast acting and highly metabolizable made of a base oil, a Cannabis oil, at least one emulsifying agent and water.
- the emulsifying agents in the cannabinoid composition are selected from the group consisting of xanthan gum, guar gum, cyclodextrin, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans.
- the base oil in the cannabinoid composition is preferably selected from the group consisting of vegetable glycerine, coconut oil and any oil high in saturated fats.
- other nut oils such as almond oil, avocado oil, canola oil, coconut oil, corn oil, cottonseed oil, grapeseed oil, hazelnut oil, olive oil, extra virgin olive oil, palm oil, peanut oil, palm seed oil, pumpkin seed oil, safflower oil, sesame oil, soy oil, sunflower oil, vegetable oil and walnut oil can be used as the base oil.
- a preferred emulsification used in the invention uses a base oil of coconut oil.
- coconut oil is one of the best sources of healthy and “good” fatty acids.
- the Cannabis oil in the composition is in a pure state that has been extracted from the marijuana plant by CO2 extraction, water extraction, butane extraction and extraction methods that leave, a zero testing for residuals.
- the Cannabis oil in the composition is selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoid oils isolated from the marijuana plant.
- ingredients such as chocolate and liquor can be added to the composition to provide different flavor profiles.
- a method to produce the invention emulsifications includes first heating a base oil, preferably, extra virgin organic coconut oil to between about 120 to 220 degrees F. Pure extracted Cannabis oil is added to the heated oil but may be added to the oil prior to heating.
- a high speed blender or similar machine
- an aqueous vehicle preferably coconut water
- the heated mixture adding at least one emulsifying agent in the amount of about 0.15% and about 2% of the total volume of finished product, to the heated oil to create a mixture.
- Percentages used herein are on a dry weight basis and are based on the total volume of the finished product.
- the blender is run at high speed for between about 30 seconds and about 2 minutes before adding the anhydrous caffeine in amounts ranging from about 10-300 mg.
- the caffeine can be added prior to adding the emulsifying agent or at the same time.
- the resulting cannabinoid emulsification is bio-available, highly metabolizable and fast acting when ingested by the user.
- the resulting emulsification is used to produce a line of THC and caffeine infused emulsifications.
- the invention process makes the Cannabis oil more bioavailable by making the oleo molecule water-soluble. Thus, upon ingestion, making it fast acting, taking effect in as little as about 15 minutes.
- Cannabis oil in the range of about 5 to 30 mg and different flavor profiles including lime, pomegranate, orange, lemon and others; and different serving sizes between about 1 and 64 oz.
- the invention sweeteners are made by starting with high quality sweeteners including sugar, coconut sugar, date sugar, stevia, and any other quality sweeteners. The sweeteners are then infused with emulsified Cannabis oil using the process described below.
- the Cannabis oil used is dissolved with alcohol, but it doesn't make the oil water-soluble.
- the invention emulsifying agents are needed to modify the Cannabis oil from its natural hydrophobic state to a “water-loving” hydrophilic state.
- the amount of Cannabis oil used depends on the desired potency, but preferably about 1 to about 10 grams of pure extracted Cannabis oil per pound of sweetener is used.
- the amount of alcohol used in the invention process is typically 4 oz per lb of sugar.
- Preferably grain alcohol is used in the invention, although other similar alcohols can be used.
- At the end of the process there is zero alcohol residue in the resulting product.
- the Cannabis oil is placed in a water bath and heated to between about 120 to 220 degrees F. for between about 4 and 30 minutes.
- the Cannabis oil is added to the alcohol and placed in a rotor blade machine and held at a temperature between about 120° F. and 220° F. for between about 1-7 minutes.
- an emulsifying agent, or combination of emulsifying agents is then added to the heated mixture in an amount between about 0.15% to 3% of the total weight of the finished product.
- This mixture is then combined with the sweetener and is heated to about 120 to about 220 degrees F. for about 10-60 minutes to complete the emulsification and to evaporate the residual alcohol from the sweetener.
- sweeteners provide a flexible, controllable, low-dose Cannabis experience, delivered in an understandable and desirable form. They can be used in beverages, such as coffee or tea.
- the invention sweeteners assure that the THC is both fast acting and highly metabolizable. It assures that the consumer experiences a consistent experience from ingesting the product, instead of having a wide variation of experiences, including how long it takes to take effect, and how the effect will be each time.
- the extracts of the invention can be mixed with other ingredients such as soda and other like liquids.
- the process for making the Cannabis infused elixirs of the invention is as follows.
- the elixirs are essentially syrups, fruit syrups, and various flavored and unflavored syrups.
- the ingredients to make a batch of the invention elixirs include an emulsifying agent in the amount of about 0.12 to about 2%.
- the syrup is heated to about 120-220 degrees F.
- the Cannabis oil is added to this heated mixture and blended in a rotor for about 1 to 7 minutes, during which time the emulsifier is added in.
- Each serving size has about 3 to 20 mg per ounce of water-soluble Cannabis oil.
- Cannabis oil in the range of about 5 to 30 mg and different flavor profiles including lime, pomegranate, orange, lemon and others; and different serving sizes between about 1 and about 64 oz.
- a Cannabis infused chocolate is provided that is bioavailable and delivers fast acting effects of the Cannabis when ingested.
- the method of making such includes use of about 5 to 10 oz of a base oil of either vegetable glycerine or coconut oil.
- a high quality liquor such as cognac or whiskey can be added but is optional.
- the base oil liquid is heated to between about 120 to 220° F.
- the Cannabis oil extract is added equal to about 110 to 1120 mg THC.
- the emulsifiers are added next, generally in the following amounts: about 0.5% lecithin, 0.15% xanthan gum, about 0.1% cyclodextrin.
- the emulsifiers can be used individually or in combination.
- the hot mixture is blended in a high speed blender or other machine, run on high speed for about 2 minutes. The mixture is allowed to cool to room temperature.
- solid and liquid (MCT) is coconut oil that has medium chain triglyceride.
- Guar gum, lecithin, and cyclodextrin were tested as emulsifying agents and provided good results.
- xanthan gum was the most effective and provided the best emulsification of the oil and water, at the lowest viscosity.
- the emulsification process that was determined the best had the added effect of making the THC more bioavailable by making the oleo molecule water-soluble. This had another added effect of making it fast acting, taking effect in as little as about 15 minutes.
- the method used to produce the invention emulsifications included first heating extra virgin organic coconut oil to between about 120 to about 220 degrees F. CO 2 extracted Cannabis oil is added.
- coconut water is added to the coconut fat (oil) to ensure emulsification.
- xanthan gum powder is added in an amount between about 0.15% and about 0.45% of the total volume of finished product. Percentages used herein are on a dry weight basis and are based on the total volume of the finished product.
- the blender is run at high speed for between 30 seconds and 2.
- the resulting emulsification is used to produce a variety of Cannabis infused products.
- the invention process makes the THC more bioavailable by making the oleo molecule water-soluble. Thus, upon ingestion, making it fast acting, taking effect in as little as 15 minutes.
- Cannabis infused products were prepared and tested in a random study group of 40 individuals.
- the products tested included Cannabis infused sugar, a cannabinoid/caffeine emulsification and a Cannabis infused elixir and are summarized in the tables below.
- Cannabis infused sugar (Serving size 1 tsp) Sugar Product #1 #2 #3 #4 #5* Cannabis Oil (mg/tsp) 20 40 20 40 40 Sugar (lbs) 5 3 10 3 Alcohol (oz) 20 12 40 12 6 Lecithin (%)** 2 2 2 1 0 Cyclodextrin (%)** 0 0 0.03 0.12 0.25 *The sugar used in this sample was maple sugar. **% of final product.
- the water-soluble cannabinoid composition and caffeine emulsifications of the invention provide a beneficial experience for people experiencing a variety of ailments: insomnia, muscle aches, anxiety, etc, or are in recovery from surgery, or in chemotherapy.
- the emulsifications make the Cannabis oil molecules hydrophilic, and thus water-soluble, which makes the THC bioavailable, faster acting, and more highly metabolizable.
- the water-soluble Cannabis of the invention provides them a convenient, and smokeless, alternative to access the cannabinoids they need to alleviate their ailments.
Abstract
Description
- This application is a Continuation-in-Part application of U.S. patent application Ser. No. 16/161,027, filed on Oct. 15, 2018, issuing as U.S. Pat. No. 10,624,844 on Apr. 21, 2020, which application is a Continuation-in-Part application of International Application No. PCT/US2017/027550 filed Apr. 14, 2017 and from International Application No. PCT/US2017/027549 filed Apr. 14, 2017, and from International Application No. PCT/US2017/027543 filed Apr. 14, 2017 which all claim priority to and the benefit of U.S. Provisional Application No. 62/323,154 filed Apr. 15, 2016 and U.S. Provisional Application No. 62/328,975 filed Apr. 28, 2016, and the specification and claims thereof are incorporated herein by reference.
- Embodiments of the present invention relate to a method of making Cannabis oil hydrophilic using emulsifiers. More particularly, embodiments of the present invention relate to a water-soluble cannabinoid composition, a cannabinoid composition with caffeine emulsification, Cannabis oil infused sweeteners and elixir that may be bio-available, fast acting and highly metabolizable.
- Cannabinoids are chemical compounds found in the Cannabis plant that interact with receptors in the brain and body to create various effects. Herbal Cannabis contains over 400 compounds including over 100 cannabinoids, which are aryl-substituted meroterpenes unique to the plant genus Cannabis. The pharmacology of most of the cannabinoids is largely unknown but the most potent psychoactive agent, Δ9-tetrahydrocannabinol (Δ9-THC, or THC), has been isolated, synthesized and much studied due to its abundance and psychoactive attributes. Other plant cannabinoids include Δ8-THC, cannabinol and cannabidiol (CBD). These and other cannabinoids have additive, synergistic or antagonistic effects with THC and may modify its actions when herbal Cannabis is smoked.
- The best studied cannabinoids include tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabinol (CBN). These structures are shown in
FIG. 1 . All cannabinoids derive from cannabigerol-type compounds and differ mainly in the way this precursor is cyclized. The classical cannabinoids are derived from their respective 2-carboxylic acids (2-COOH) by decarboxylation (catalyzed by heat, light, or alkaline conditions). - The isolation of THC came from an Israeli chemist by the name of Raphael Mechoulam. In 1964, Mechoulam isolated and synthesized THC from Lebanese hashish, marking the beginning of Cannabis research that would lead to the discovery of many other cannabinoids, cannabinoid receptors throughout the body, and “endocannabinoids”—the THC-like compounds the human body naturally produces to maintain stability and health.
- CBD and THC levels tend to vary among different plants. Marijuana grown for recreational purposes often contains more THC than CBD. However, by using selective breeding techniques, Cannabis breeders can create varieties with high levels of CBD and next to zero levels of THC.
- Humans and many other animals have receptor systems that THC binds to, and therefore can also reap the benefits of cannabinoids for both health and enjoyment. The endocannabinoid system (or “ECS”), is a group of specialized signaling chemicals, their receptors, and the metabolic enzymes that produce and break them down. These endocannabinoid chemical signals act on some of the same brain and immune cell receptors (CB1 and CB2) that plant cannabinoids like CBD and THC act on.
- THC works by binding to cannabinoid receptors concentrated in the brain and central nervous system to produce psychoactive effects. The main difference between THC and CBD, both of which are very popular cannabinoids, is in their psychoactive effects. THC elicits strong cerebral euphoria, while CBD lacks psychoactive effects altogether. This basically comes down to the fact that THC activates CB1 receptors in the human brain while CBD does not.
- It is well known that cannabinoids, especially CBD and THC have many medicinal benefits. CBD's subtle effects are primarily felt in pain, inflammation, and anxiety relief, as well as other medicinal benefits. CBD also does not have any adverse side effects that may occur with consumption of THC. Unlike THC, CBD also does not cause a high. This makes CBD a significant advantage as a medicine, since health professionals prefer treatments with minimal side effects. CBD also appears to counteract the sleep-inducing effects of THC, which may explain why some strains of Cannabis are known to increase alertness. CBD also acts to reduce the intoxicating effects of THC, such as memory impairment and paranoia.
- THC has a wide range of short-term effects which may or may not be experienced depending on the individual and their body chemistry. Some positive short-term effects of THC include: elation, relaxation, sedation, pain relief, energy, hunger, drowsiness, slowed perception of time and laughter.
- There are a variety of medical conditions for which THC offers benefits. The conditions include Post Traumatic Stress Disorder, neuropathic and chronic pain, insomnia, nausea, inflammation, arthritis, migraines, Cancer, Crohn's disease, fibromyalgia, Alzheimer's disease, Multiple sclerosis, Glaucoma, Attention deficit hyperactivity disorder (“ADHD”), sleep apnea and appetite loss.
- Both CBD and THC have been found to present no risk of lethal overdose. However, to reduce potential side effects, medical users are better off using Cannabis with higher levels of CBD.
- Today the most common way to consume THC is through smoking although they can be consumed orally. However, known methods for orally administered THC have reduced bioavailability due to low absorption and high first-pass metabolism in the digestive system. Thus, there is a need for aqueous cannabinoid solutions.
- Decarboxylation of the THC occurs with heating and is the key to enjoying THC, whether it is consumed by smoking or ingesting. In its raw form, Cannabis is non-psychoactive, with its primary cannabinoid being THCA. However, by applying heat, either when lighting it in a pipe or cooking it into oil, the THCA is converted to THC.
- The invention method provides an advantageous alternative to smoking Cannabis by providing a water-soluble cannabinoid composition for oral ingestion that is bioavailable, highly metabolizable and fast acting.
- As an aromatic terpenoid, THC has a very low solubility in water, but good solubility in most organic solvents, specifically lipids and alcohols.
- The problem with edible Cannabis products is they take a varied amount of time to take effect due to the liver's varied ability to process the THC molecule. Depending on liver function at the time, between 2-6% of the THC is able to be metabolized. This process makes it so the THC is absorbed in the esophagus and soft tissues, making it faster acting and more highly metabolizable.
- Unlike anything currently known, one or more purposes of embodiments of the present invention is to provide a water-soluble cannabinoid composition, and/or a cannabinoid emulsification (with or without caffeine), and/or Cannabis infused sweeteners and Cannabis infused elixirs to create Cannabis oil infused products for medical and recreational use that are bioavailable, fast acting and highly metabolized, with consistent results that take place in a consistent amount of time. In general, elixirs are healing botanicals known to address specific imbalances yet, they are not necessarily teaching the body to mimic the healing chemistry in order for the body to continue healing. Also, elixirs are made with delicious flavoring agents, flowers and healthy sweeteners, as well as use a different ratio of medicinal potency. Elixirs are usually a 1:3 or 1:4 in liquid to herb extraction.
- In making the sweeteners and elixirs according a method of the present invention, a method to make Cannabis oil water-soluble is used which uses a combination of emulsifiers and variations in time and temperature of the reaction steps. The process results in a Cannabis infused sweeteners and elixirs which provide fast acting, bioavailability and highly metabolizable delivery of the Cannabis oil, either alone or in combination with other edible products.
- Another purpose of the invention is to provide a line of Cannabis oil infused sugars and elixirs that share a base of coconut water infused with coconut fat and to sell the products to wholesale distributors for retail sale in legal dispensaries.
- A purpose of an embodiment of the invention is to provide a method to make Cannabis oil water-soluble using a combination of emulsifiers and variations in time and temperature of the reaction steps. One result of the process is a water-soluble, hydrophilic cannabinoid composition, and/or a cannabinoid emulsification and/or Cannabis infused sweeteners and Cannabis infused elixirs which can be used in a variety of edible products providing fast acting, bioavailability and highly metabolizable delivery of the Cannabis oil.
- Another purpose of the invention is to provide a line of Cannabis oil and caffeine edible products that share a base of coconut water infused with coconut fat and to sell the products to wholesale distributors for retail sale in legal dispensaries.
- Another purpose of the invention is to provide a line of Cannabis oil and caffeine infused sugars and elixirs that share a base of coconut water infused with coconut fat and to sell the products to wholesale distributors for retail sale in legal dispensaries.
- More specifically a purpose of the invention is to use the water-soluble cannabinoid composition, and/or a cannabinoid emulsification and/or a Cannabis infused sweeteners and elixirs to treat Post Traumatic Stress Disorder, neuropathic and chronic pain, insomnia, nausea, inflammation, arthritis, migraines, Cancer, Crohn's disease, fibromyalgia, Alzheimer's disease, Multiple sclerosis, Glaucoma, Attention deficit hyperactivity disorder (“ADHD”), sleep apnea and appetite loss.
- Yet another purpose of an embodiment of the water-soluble Cannabis oil composition, and/or emulsification, and/or sugars and elixirs is to treat pain, inflammation, and anxiety relief.
- More specifically, the water-soluble Cannabis oil composition, and/or the emulsification, and/or the sugars and elixirs can be combined with chocolate and/or liquor to create edible products.
- Yet another purpose of embodiments of the present invention provides that the composition, emulsification, and/or sugars and elixirs can be used to produce other edible products at home or professionally with predictable results, including being fast-acting, and highly metabolizable, which are referred to herein as super-charged. This lets consumers know that the invention products have markedly different results than other products. These compositions can be marketed in many forms, both in retail and wholesale manufacturing, as well as aiding companies with quality products to use for research and development.
- In one or more embodiments of the present invention, the above purposes, as well as others which will be apparent, are achieved generally by a method of making Cannabis oil hydrophilic by using a combination of emulsifiers and variations in time and temperature of the reaction steps, and/or cannabinoid emulsification made of at least one emulsifying agent; an aqueous vehicle; a base oil; Cannabis oil; and caffeine, and/or Cannabis infused sweetener comprising Cannabis oil; at least one emulsifying agent selected from the group consisting of xanthan gum, guar gum, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans and a sweetener. The resulting cannabinoid emulsification is bio-available, highly metabolizable and fast acting when ingested by the user.
- In one embodiment, the specific steps in making the Cannabis oil hydrophilic include first heating a base oil in the range of about 120 to 220° F. The Cannabis oil is added to this heated oil (pre heating or post heating) to create a mixture which is then blended at a high speed. At least one emulsifying agent is added to the hot mixture while blending is continued. Water is then added to form the composition wherein the Cannabis oil is hydrophilic and is soluble in water.
- This method modifies normally hydrophobic, or “water-repelling”, Cannabis oil into a hydrophilic Cannabis oil alone or when combined with one or more of the following: an emulsification, sweetener/sugar and/or elixir that is bio-available, highly metabolizable and fast acting when ingested by the user. The Cannabis oil produced by this method is suitable for use in emulsifications and a component of sugars and elixirs.
- It is a preferred process parameter that while blending the mixture it is maintained at a temperature in the range of about 120 to 220° F.
- In one embodiment, a sweetener used is selected from the group consisting of white sugar, cane sugar, raw sugar, fructose, turbinado sugar, coconut sugar, date sugar, liquid stevia, liquid sugar, powdered sugar, brown sugar, muscovado sugar, honey, agave and other like sweeteners. The sweetener component is present in the range of about 98% to about 99.88% of the Cannabis infused sweetener. Alternatively, the sweetener is present in the range of about 50%-60%, 60-70%, 70-80%, 80-90% or 90-99.9% for example.
- At least one emulsifying agent is used in the invention process which is selected from the group consisting of xanthan gum, guar gum, cyclodextrin, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans.
- A Cannabis oil is selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoid oils isolated from the marijuana plant. The Cannabis oil is present in the range of about 1.5 mg to 20 mg per gram of sweetener.
- The emulsifying agent is present in the range of about 0.12% to 2% of the total sweetener. In preferred embodiments, the emulsifying agent is a combination of at least two emulsifying agents which can be the same or different. In a preferred embodiment, the emulsifying agents include cyclodextrin in combination with at least one selected from the group consisting of xanthan gum, guar gum, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans.
- The aqueous vehicle is selected from the group consisting of coconut water, fruit juice, milk and water. The aqueous vehicle is in the range of about 60% to 99.9% of the emulsification. The preferred vehicle is coconut water. Alternatively, the aqueous vehicle is present in the range of about 50%-60%, 60-70%, 70-80%, 80-90% or 90-99.9% for example.
- The base oil is selected from the group consisting of vegetable glycerine, almond oil, avocado oil, canola oil, coconut oil, corn oil, cottonseed oil, grapeseed oil, hazelnut oil, olive oil, extra virgin olive oil, palm oil, peanut oil, palm seed oil, pumpkin seed oil, safflower oil, sesame oil, soy oil, sunflower oil, vegetable oil and walnut oil and any oil high in saturated fats. The base oil is preferably in the range of about 0.1% to 40% of the emulsification. Alternatively, the base oil is present in the range of about 0.1%-5%, 5-10%, 10-20%, 20-30% or 30-40% for example.
- The Cannabis oil used in the invention is in a pure state. The Cannabis oil used can be extracted from the marijuana plant by CO2 extraction, water extraction, butane extraction and extraction methods that leave a zero testing for residuals.
- The Cannabis oil used in the invention is selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoid oils isolated from the marijuana plant.
- In a preferred embodiment, a Cannabis infused elixir is provided comprising Cannabis oil; at least one emulsifying agent; a sweetener selected from the group consisting of white sugar, cane sugar, raw sugar, fructose, turbinado sugar, coconut sugar, date sugar, liquid stevia, liquid sugar, powdered sugar, brown sugar, muscovado sugar, honey, agave and other like sweeteners and flavoring extracts or fruit syrups.
- The sweetener is present in the range of about 98% to 99.8% of the elixir.
- The Cannabis infused elixir includes Cannabis oil is bio-available, highly metabolizable and fast acting when ingested by the user.
- As in the sweetener embodiment, the Cannabis oil used in the elixir is selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoid oils isolated from the marijuana plant. The Cannabis oil is present in the range of about 3 mg to 50 mg per ounce of elixir.
- The Cannabis oil and/or elixir is added to the mixture or a drink solution, such as a carbonated or flat water solution, in the range of about 5 mg to 20 mg per 2 ounces of the composition or a ratio between about 1:3 to 1:4 to create a liquid beverage. The base oil is present in the range of about 0.5 grams to 5 grams of base oil per about 1 ounce of the composition.
- The emulsifying agent is in the range of about 0.15% and about 2% of the total volume of the emulsification and/or the emulsifying agent is present in the range of about 0.15% to about 2% of the elixir.
- The invention also provides a water-soluble cannabinoid composition that is bioavailable, fast acting and highly metabolizable.
- The emulsifying agent is selected from the group consisting of xanthan gum, guar gum, cyclodextrin, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans.
- The base oil in the cannabinoid composition is preferably selected from the group consisting of vegetable glycerine, coconut oil and any oil high in saturated fats. However, other nut oils such as almond oil, avocado oil, canola oil, coconut oil, corn oil, cottonseed oil, grapeseed oil, hazelnut oil, olive oil, extra virgin olive oil, palm oil, peanut oil, palm seed oil, pumpkin seed oil, safflower oil, sesame oil, soy oil, sunflower oil, vegetable oil and walnut oil can be used as the base oil.
- The Cannabis oil in the composition is in a pure state that has been extracted from the marijuana plant by CO2 extraction, water extraction, butane extraction and extraction methods that leave a zero testing for residuals.
- The Cannabis oil in the composition is selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoid oils isolated from the marijuana plant.
- Other ingredients such as chocolate and liquor can be added to the composition to provide different flavor profiles.
- In a preferred embodiment the emulsifying agent is a combination of at least two emulsifying agents. In a most preferred embodiment cyclodextrin is used in combination with at least one other emulsifying agent selected from the group consisting of xanthan gum, guar gum, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans.
- The Cannabis oil in the emulsification is in the range of about 5 mg to 30 mg per 2 ounces of the emulsification.
- Caffeine is present in one embodiment of the emulsification in the range of about 10 to 300 mg per 2 ounces of the emulsification. The caffeine can be in anhydrous form.
- In the emulsification the base oil to aqueous vehicle ratio is between about 1 to 10 grams of base oil per about 2 ounces of the emulsification.
- The invention also provides a method for making cannabinoid emulsifications comprising the steps of heating a base oil, preferably coconut oil, to between about 120 to 220 degrees F. Adding at least one emulsifying agent, caffeine and Cannabis oil to an aqueous vehicle and adding to the heated coconut oil to create a mixture. Blending the mixture in a high speed machine, while holding the temperature between about 120 to 220 degrees F. to emulsify the mixture and then adding caffeine to the mixture.
- The emulsifying agents are added in an amount between 0.15% and 2% of the total volume of the mixture and are selected from the group consisting of xanthan gum, guar gum, cyclodextrin, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans.
- The hot mixture is blended at high speed for between 30 seconds and 2 minutes. The resulting cannabinoid emulsification is bio-available, highly metabolizable and fast acting when ingested by the user.
- In preferred embodiments the emulsifying agent is a combination of at least two emulsifying agents. In a most preferred embodiment the emulsifying agent is a combination of xanthan gum and cyclodextrin, where the cyclodextrin and xanthan gum are each present in the amount of 0.12 to 2%.
- An embodiment of the present invention is a cannabinoid infused ingestible composition comprising a cannabinoid oil; a compound that forms an inclusion complex with the cannabinoid oil; and a thickener; wherein the cannabinoid oil is the only oil in the composition. The composition preferably further comprises a sweetener. The sweetener is preferably selected from the group consisting of white sugar, cane sugar, raw sugar, fructose, turbinado sugar, coconut sugar, date sugar, stevia, liquid stevia, liquid sugar, powdered sugar, brown sugar, muscovado sugar, maple sugar, honey, and agave. The compound preferably comprises cyclodextrin. The thickener preferably comprises a gum. The gum preferably comprises xanthan gum. The cannabinoid preferably comprises tetrahydrocannabinol (THC) and/or cannabidiol (CBD). The cannabinoid is preferably bio-available, highly metabolizable and fast acting when ingested. The compound and the thickener each preferably comprise about 0.12% to 2% of the composition. The composition preferably comprises from about 0.01% to 4% of both the compound and the thickener, more preferably from about 0.15% to 3% of both the compound and the thickener. The composition preferably comprises equal percentages of the compound and the thickener.
- Another embodiment of the present invention is a cannabinoid infused composition consisting essentially of a cannabinoid oil; an alcohol; water; a compound that forms an inclusion complex with the cannabinoid oil; and a thickener. The compound preferably comprises cyclodextrin. The thickener preferably comprises a gum. The gum preferably comprises xanthan gum. The cannabinoid preferably comprises tetrahydrocannabinol (THC) and/or cannabidiol (CBD). The cannabinoid is preferably bio-available, highly metabolizable and fast acting when ingested. The compound and the thickener each comprise 0.12% to 2% of the composition. The composition preferably comprises about 0.01% to 4% of both the compound and the thickener, and more preferably about 0.15% to 3% of both the compound and the thickener. The composition preferably comprises equal percentages of the compound and the thickener.
- Another embodiment of the present invention is a cannabinoid infused composition consisting essentially of a cannabinoid oil; water; a compound that forms an inclusion complex with the cannabinoid oil; a thickener; and a sweetener. The sweetener is preferably selected from the group consisting of white sugar, cane sugar, raw sugar, fructose, turbinado sugar, coconut sugar, date sugar, stevia, liquid stevia, liquid sugar, powdered sugar, brown sugar, muscovado sugar, maple sugar, honey, and agave. The compound preferably comprises cyclodextrin. The thickener preferably comprises a gum. The gum preferably comprises xanthan gum. The cannabinoid preferably comprises tetrahydrocannabinol (THC) and/or cannabidiol (CBD). The compound and the thickener each preferably comprise about 0.12% to 2% of the composition. The composition preferably comprises about 0.01% to 4% of both the compound and the thickener, and more preferably about 0.15% to 3% of both the compound and the thickener. The composition preferably comprises equal percentages of the compound and the thickener.
- Another embodiment of the present invention is a cannabinoid infused composition consisting essentially of a cannabinoid oil; a compound that forms an inclusion complex with the cannabinoid oil; a thickener; and a sweetener. The sweetener is preferably selected from the group consisting of white sugar, cane sugar, raw sugar, fructose, turbinado sugar, coconut sugar, date sugar, stevia, liquid stevia, liquid sugar, powdered sugar, brown sugar, muscovado sugar, maple sugar, honey, and agave. The compound preferably comprises cyclodextrin. The thickener preferably comprises a gum. The gum preferably comprises xanthan gum. The cannabinoid preferably comprises tetrahydrocannabinol (THC) and/or cannabidiol (CBD). The compound and the thickener each preferably comprise about 0.12% to 2% of the composition. The composition preferably comprises about 0.01% to 4% of both the compound and the thickener, and more preferably about 0.15% to 3% of both the compound and the thickener. The composition preferably comprises equal percentages of the compound and the thickener.
- Other objects, features and advantages of the present invention will be apparent when the detailed description of the preferred embodiments of the invention is considered which should be construed in an illustrative and not limiting sense.
- The accompanying drawings, which are incorporated into and form a part of the specification, illustrate one or more embodiments of the present invention and, together with the description, serve to explain the principles of the invention. The drawings are only for the purpose of illustrating one or more embodiments of the invention and are not to be construed as limiting the invention. In the drawings:
-
FIG. 1 is the formula for THC, cannabinol and cannabidiol and structure; -
FIG. 2 is the structure for Xanthan Gum; -
FIG. 3 is the structure of Guar Gum. -
FIG. 4 is a chemical structure and the molecular shape of B-cyclodextrin (BCD); -
FIG. 5 is a chemical structure of Lecithin; -
FIG. 6 is a chemical structure of Carrageen (kappa); and -
FIG. 7 is a chemical structure of a monoglyceride. - One embodiment of the present invention provides a method of making Cannabis oil hydrophilic. The process of the invention modifies normally hydrophobic, or “water-repelling”, Cannabis oil into hydrophilic Cannabis oil that is bio-available, highly metabolizable and fast acting when ingested by the user.
- Another embodiment provides a unique emulsified combination of Cannabis oil, caffeine, and a base oil and aqueous vehicle, which are respectively, preferably coconut oil, and coconut water. Coconut oil is one of the best sources of excellent fatty acids. Emulsified with coconut water, Cannabis oil and caffeine provide a beneficial experience for people experiencing a variety of ailments: insomnia, muscle aches, anxiety, etc., or are in recovery from surgery, or in chemotherapy. The emulsification makes the Cannabis oil molecules water-soluble, by modification from its normal hydrophobic state into a hydrophilic (“water-loving”), which makes the Cannabis oil bioavailable, faster acting, and more highly metabolizable.
- Yet another embodiment provides a Cannabis infused sweetener comprising Cannabis oil; at least one emulsifying agent selected from the group consisting of xanthan gum, guar gum, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans and a sweetener; and Cannabis infused elixir comprising Cannabis oil; at least one emulsifying agent; a sweetener selected from the group consisting of white sugar, cane sugar, raw sugar, fructose, turbinado sugar, coconut sugar, date sugar, liquid stevia, liquid sugar, powdered sugar, brown sugar, muscovado sugar, honey, agave and other like sweeteners and flavoring extracts or fruit syrups.
- In one instance, both sweetener and elixir embodiments the Cannabis oil therein has been modified from its normal hydrophobic state into a hydrophilic (“water-loving”) state that is bio-available, highly metabolizable and fast acting when ingested by the user.
- Bioavailability refers to the degree to which food nutrients, in this invention, Cannabis oil, are available for absorption and utilization in the body. Bioavailability typically applies to nutrients and drugs which pass through first-pass metabolism, i.e. orally consumed substances. Anything absorbed in the gut first passes through the liver before reaching the rest of the circulation, and both the gut and liver may metabolize it to some extent.
- Metabolizable refers to the process of changing food/substances into a form that can be used by your body.
- The process steps of an embodiment of the invention include first heating a base oil in the range of about 120 to 220° F. The Cannabis oil is added to this heated oil to create a mixture which is then blended at a high speed. At least one emulsifying agent is added to the hot mixture while blending is continued. Water is then added to form the composition wherein the Cannabis oil is hydrophilic and is soluble in water.
- It is a preferred process parameter that while blending the mixture it is maintained at a temperature in the range of about 120 to 220° F.
- The cannabinoid emulsification embodiment of the invention is made of at least one emulsifying agent; an aqueous vehicle; a base oil; Cannabis oil; and caffeine.
- Emulsions are produced by dispersing normally unmixable material into another by mixing, colloidal milling or homogenization. The surface-active qualities of emulsifiers of the invention make them effective emulsifying agents that reduce mixing time and maintain the stability of the dispersion.
- The emulsifying agent in the invention is present in the range of about 0.15% to 2% of the composition. At least one emulsifying agent is used in the invention process which is selected from the group consisting of xanthan gum, guar gum, cyclodextrin, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans. In preferred embodiments, the emulsifying agent is a combination of at least two different emulsifying agents.
- Cannabis oil, including THC and CBD, are not water-soluble, so it needs to be “trapped” in something with dual polarity—that is, a compound that reconciles the fact that water is polar and the cannabinoid is not. The emulsifiers provide this. Once trapped in the compound, the THC has new de facto properties, like the ability to dissolve in water, distribute itself evenly, and stay suspended in the solution. It also displays increased bioavailability: while the same amount of Cannabis oil in an edible can take up to two hours to reach the bloodstream, the effects of water-soluble Cannabis oil dissolved in water can be felt more acutely, in as little as 10 minutes.
- It is known that cannabinoids are soluble in fat. It is also known that only water-soluble substances can pass the intestine membrane. Fat is itself not water-soluble because it is like cannabinoids, uncharged. Fat absorption into the membrane requires substances with a dipole character to build up vehicles which can connect at the outer surface with water (charged side) and at the inner surface with the fat and the THC (uncharged side).
- The specific emulsifiers used in the invention are detailed below.
- Xanthan gum, which is also called xanthene, has the chemical formula C13H10O. Its molecular weight is 182.22 grams/mol.
FIG. 2 shows the chemical structure of xanthan gum. - In general, xanthan gum is a substance made by fermenting bacteria with sugars. It is an additive found in both foods and medicines. As a food additive, this substance is utilized either as a thickener or stabilizer. This compound has a variety of uses in medicine, such as in the treatment of diabetes, cholesterol and dry mouth.
- Specifically, xanthan gum is a polysaccharide secreted by the bacterium Xanthomonas campestris. Its known uses, prior to the invention, is as a food additive and rheology modifier, commonly used as a food thickening agent (in salad dressings, for example) and a stabilizer (in cosmetic products, for example, to prevent ingredients from separating). As seen in
FIG. 1 , it is composed of pentasaccharide repeat units, comprising glucose, mannose, and glucuronic acid in the molar ratio 2:2:1. It is produced by the fermentation of glucose, sucrose, or lactose. After a fermentation period, the polysaccharide is precipitated from a growth medium with isopropyl alcohol, dried, and ground into a fine powder. Later, it is added to a liquid medium to form the gum. - Chemically, guar gum is a polysaccharide composed of the sugars galactose and mannose.
FIG. 3 shows that the backbone is a linear chain of β1,4-linked mannose residues to which galactose residues are 1,6-linked at every second mannose, forming short side-branches. - In water, guar gum is nonionic and hydrocolloidal. It is not affected by ionic strength or pH, but will degrade at extreme pH and temperature (e.g. pH 3 at 50° C.). It remains stable in solution over pH range of about 5-7. Strong acids cause hydrolysis and loss of viscosity, and alkalis in strong concentration also tend to reduce viscosity. It is insoluble in most hydrocarbon solvents. The viscosity attained is dependent on time, temperature, concentration, pH, rate of agitation and practical size of the powdered gum used. The lower the temperature, the lower the rate at which viscosity increases and the lower the final viscosity. Above 80°, the final viscosity is slightly reduced. The finer guar powders swell more rapidly than coarse powdered gum. Guar gum has almost eight times the water-thickening potency of cornstarch—only a very small quantity is needed for producing sufficient viscosity. Thus, it can be used in various multiphase formulations: as an emulsifier because it helps to prevent oil droplets from coalescing, and/or as a stabilizer because it helps to prevent solid particles from settling.
- Cyclodextrins are a group of structurally related natural products formed during bacterial digestion of cellulose. These cyclic oligosaccharides consist of (α-1,4)-linked α-D-glucopyranose units and contain a somewhat lipophilic central cavity and a hydrophilic outer surface. Due to the chair conformation of the glucopyranose units, the cyclodextrins are shaped like a truncated cone rather than perfect cylinders. The hydroxyl functions are oriented to the cone exterior with the primary hydroxyl groups of the sugar residues at the narrow edge of the cone and the secondary hydroxyl groups at the wider edge. The central cavity is lined by the skeletal carbons and ethereal oxygens of the glucose residues, which gives it a lipophilic character. The polarity of the cavity has been estimated to be similar to that of an aqueous ethanolic solution.
- The natural α-, β- and γ-cyclodextrin (αCD, βCD and γCD) consist of six, seven, and eight glucopyranose units, respectively. The natural cyclodextrins, in particular βCD, are of limited aqueous solubility meaning that complexes resulting from interaction of lipophiles with these cyclodextrin can be of limited solubility resulting in precipitation of solid cyclodextrin complexes from water and other aqueous systems. In fact, the aqueous solubility of the natural cyclodextrins is much lower than that of comparable acyclic saccharides. This is thought to be due to relatively strong intermolecular hydrogen bonding in the crystal state. Substitution of any of the hydrogen bond forming hydroxyl groups, even by lipophilic methoxy functions, results in dramatic improvement in their aqueous solubility. Water-soluble cyclodextrin derivatives of commercial interest include the hydroxypropyl derivatives of βCD and γCD, the randomly methylated β-cyclodextrin (RMβCD), and sulfobutylether β-cyclodextrin sodium salt (SBEβCD).
-
FIG. 4 and Table 1 were taken from an article entitled “Cyclodextrins” (A. Magnúsdóttir, M. Másson and T. Loftsson, J. Incl. Phenom. Macroc. Chem. 44, 213-218, 2002). -
TABLE 1 Water solubility of cyclodextrins. Solubility MW b in water c Cyclodextrin n R = H or Subst. a (Da) (mg/L) α-Cyclodextrin (αCD) 0 −H 0 972 145 β-Cyclodextrin (βCD) 1 −H 0 1135 18.5 2-Hydroxypropyl-β-cyclodextrin 1 −CH2CHOHCH3 0.65 1400 >600 (HPβCD; Kleptose ® HPB) Sulfobutylether β-cyclodextrin 1 −(CH2)4SO3Na+ 0.9 2163 >500 sodium salt (SBEβCD; Captisol ®) Randomly methylated β- 1 −CH3 1.8 1312 >500 cyclodextrin (RMβCD) γ-Cyclodextrin (γCD) 2 −H 0 1297 232 2-Hydroxypropyl-γ-cyclodextrin 2 −CH2CHOHCH3 0.6 1576 >500 (HPγCD) a Average number of substituents per glucose repeat unit; b MW: Molecular weight; c Solubilityin pure water at approx. 25° C. - Cyclodextrins create highly concentrated and water-soluble granules. Cyclodextrins are circular structures of sugar molecules that are known to absorb other compounds into their center. They form inclusion complexes with poorly water-soluble compounds. Acting like a molecule magnet, cyclodextrins absorb other molecules and assume their properties. These molecules can absorb up to 60% of their weight in alcohol while remaining in powdered form. It isn't until you mix them with water that they dissolve.
- Experiments with THC-cyclodextrin compounds increase THC water solubility by nearly 1000 times. For this reason, in preferred embodiments, the emulsifying agent is a combination of at least two different emulsifying agents with at least one being cyclodextrin and the other emulsifying agent selected from the group consisting of xanthan gum, guar gum, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans.
- It is noted that cyclodextrin is very expensive and some versions even cause unwanted side effects when ingested. In the invention a lesser amount of cyclodextrin is used in combination with other emulsifiers that are less costly to provide the same or better solubility results. This provides an economic solution to using a lesser amount of cyclodextrin with the benefits at lower cost.
- Lecithin
- Lecithins are used in the invention as emulsifiers. They are surface-active; simultaneous hydrophilic (water-loving) and hydrophobic (water-repelling) properties enable lecithins to make stable blends of materials that otherwise do not mix easily and tend to separate.
- Lecithin is a generic term to designate any group of yellow-brownish fatty substances occurring in animal and plant tissues, which are amphiphilic—they attract both water and fatty substances (and so are both hydrophilic and lipophilic). Lecithins are generally used for smoothing food textures, dissolving powders (emulsifying), homogenizing liquid mixtures, and repelling sticking materials. Lecithins are composed of phosphoric acid with choline, glycerol or other fatty acids usually glycolipids or triglyceride. Glycerophospholipids in lecithin include phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, and phosphatidic acid.
- When added to Cannabis coconut oil lecithin increases absorption of THC and other cannabinoids into the cell membranes and speeds up the process.
- Carrageens are a family of linear sulphated polysaccharides that are extracted from red edible seaweeds. They are widely used in the food industry, for their gelling, thickening, and stabilizing properties. Their main application is in dairy and meat products, due to their strong binding to food proteins. There are three main varieties of carrageenan, which differ in their degree of sulphation. Kappa-carrageenan has one sulphate group per disaccharide, Iota-carrageenan has two, and Lambda-carrageenan has three.
- Monoglycerides are a class of glycerides which are composed of a molecule of glycerol linked to a fatty acid via an ester bond. As glycerol contains both primary and secondary alcohol groups two different types of monoglycerides may be formed; 1-monoacylglycerols where the fatty acid is attached to a primary alcohol, or a 2-monoacylglycerols where the fatty acid is attached to the secondary alcohol.
- Monoglycerides are primarily used as surfactants, usually in the form of emulsifiers. Together with diglycerides, monoglycerides are commonly added to commercial food products in small quantities which helps to prevent mixtures of oils and water from separating.
- The base oil is present in the range of about 0.5 grams to 5 grams of base oil per 1 ounce of the composition.
- The base oil is preferably in the range of about 0.1% to 40% of the emulsification.
- The base oil is preferably selected from the group consisting of vegetable glycerine, coconut oil and any oil high in saturated fats. Nut oils are also used in the invention process. The nut oils are selected from the group consisting of almond oil, avocado oil, canola oil, coconut oil, corn oil, cottonseed oil, grapeseed oil, hazelnut oil, olive oil, extra virgin olive oil, palm oil, peanut oil, palm seed oil, pumpkin seed oil, safflower oil, sesame oil, soy oil, sunflower oil, vegetable oil and walnut oil.
- An aqueous vehicle is selected from the group consisting of coconut water, fruit juice, milk and water. The aqueous vehicle is in the range of about 60% to 99.9% of the emulsification. The preferred vehicle is coconut water.
- In the emulsification the base oil to aqueous vehicle ratio is between about 1 to 10 grams of base oil per 2 ounces of the emulsification.
- The Cannabis oil used in embodiments of the invention is in a pure state. This is important since the intended end use of the products of the invention are to be ingested by humans for medical or recreational use, where permitted.
- The Cannabis oil used can be extracted from the marijuana plant by CO2 extraction, water extraction, butane extraction and extraction methods that leave a zero testing for residuals. Representative structures of the Cannabis oil are illustrated in
FIG. 1 . - The Cannabis oil used in an embodiment of the invention is selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoid oils isolated from the marijuana plant.
- For example, the Cannabis oil in the emulsification is in the range of about 5 mg to about 30 mg per about 2 ounces of the emulsification. The Cannabis oil in the sweetener is present in the range of about 1.5 mg to about 20 mg per gram of sweetener. The Cannabis oil present in the elixir is in the range of about 3 mg to about 50 mg per ounce of elixir. In one embodiment, the Cannabis oil is not completely emulsified. The Cannabis oil remaining un-emulsified is absorbed by the body at a different/longer rate than the emulsified Cannabis oil.
- Caffeine may be present/added in an embodiment of an emulsification in the range of about 10 to about 300 mg per about 2 ounces of the emulsification. The caffeine can be in anhydrous form.
- The Cannabis oil is added to the mixture and is present in the range of about 5 mg to 20 mg per about 2 ounces of the composition.
- The sweetener is used in both the infused sweetener and white sugar, cane sugar, raw sugar, fructose, turbinado sugar, coconut sugar, date sugar, liquid stevia, liquid sugar, powdered sugar, brown sugar, muscovado sugar, honey, agave and other like sweeteners. The sweetener component is present in the range of about 98% to about 99.88% of the Cannabis infused sweetener or Cannabis infused elixir.
- As a result of one invention method, a water-soluble cannabinoid composition is also provided that is bioavailable, fast acting and highly metabolizable made of a base oil, a Cannabis oil, at least one emulsifying agent and water.
- The emulsifying agents in the cannabinoid composition are selected from the group consisting of xanthan gum, guar gum, cyclodextrin, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans.
- The base oil in the cannabinoid composition is preferably selected from the group consisting of vegetable glycerine, coconut oil and any oil high in saturated fats. However, other nut oils such as almond oil, avocado oil, canola oil, coconut oil, corn oil, cottonseed oil, grapeseed oil, hazelnut oil, olive oil, extra virgin olive oil, palm oil, peanut oil, palm seed oil, pumpkin seed oil, safflower oil, sesame oil, soy oil, sunflower oil, vegetable oil and walnut oil can be used as the base oil.
- A preferred emulsification used in the invention uses a base oil of coconut oil. Coconut oil is one of the best sources of healthy and “good” fatty acids.
- The Cannabis oil in the composition is in a pure state that has been extracted from the marijuana plant by CO2 extraction, water extraction, butane extraction and extraction methods that leave, a zero testing for residuals.
- The Cannabis oil in the composition is selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoid oils isolated from the marijuana plant.
- Other ingredients such as chocolate and liquor can be added to the composition to provide different flavor profiles.
- A method to produce the invention emulsifications, includes first heating a base oil, preferably, extra virgin organic coconut oil to between about 120 to 220 degrees F. Pure extracted Cannabis oil is added to the heated oil but may be added to the oil prior to heating. In a high speed blender (or similar machine) an aqueous vehicle, preferably coconut water, is added to the coconut fat (oil) to ensure emulsification. While blending the heated mixture, adding at least one emulsifying agent in the amount of about 0.15% and about 2% of the total volume of finished product, to the heated oil to create a mixture. Percentages used herein are on a dry weight basis and are based on the total volume of the finished product. The blender is run at high speed for between about 30 seconds and about 2 minutes before adding the anhydrous caffeine in amounts ranging from about 10-300 mg. Alternatively, the caffeine can be added prior to adding the emulsifying agent or at the same time. The resulting cannabinoid emulsification is bio-available, highly metabolizable and fast acting when ingested by the user. The resulting emulsification is used to produce a line of THC and caffeine infused emulsifications. The invention process makes the Cannabis oil more bioavailable by making the oleo molecule water-soluble. Thus, upon ingestion, making it fast acting, taking effect in as little as about 15 minutes.
- Other variations include various doses of Cannabis oil in the range of about 5 to 30 mg and different flavor profiles including lime, pomegranate, orange, lemon and others; and different serving sizes between about 1 and 64 oz.
- The invention sweeteners are made by starting with high quality sweeteners including sugar, coconut sugar, date sugar, stevia, and any other quality sweeteners. The sweeteners are then infused with emulsified Cannabis oil using the process described below.
- The Cannabis oil used is dissolved with alcohol, but it doesn't make the oil water-soluble. The invention emulsifying agents are needed to modify the Cannabis oil from its natural hydrophobic state to a “water-loving” hydrophilic state. The amount of Cannabis oil used depends on the desired potency, but preferably about 1 to about 10 grams of pure extracted Cannabis oil per pound of sweetener is used.
- The amount of alcohol used in the invention process is typically 4 oz per lb of sugar. Preferably grain alcohol is used in the invention, although other similar alcohols can be used. At the end of the process there is zero alcohol residue in the resulting product.
- The Cannabis oil is placed in a water bath and heated to between about 120 to 220 degrees F. for between about 4 and 30 minutes. The Cannabis oil is added to the alcohol and placed in a rotor blade machine and held at a temperature between about 120° F. and 220° F. for between about 1-7 minutes. During this process, an emulsifying agent, or combination of emulsifying agents, is then added to the heated mixture in an amount between about 0.15% to 3% of the total weight of the finished product.
- This mixture is then combined with the sweetener and is heated to about 120 to about 220 degrees F. for about 10-60 minutes to complete the emulsification and to evaporate the residual alcohol from the sweetener. There is about 1 to about 4 grams of oil to about 4 oz of grain alcohol per pound of sweetener.
- Possible variations include: percentage of emulsifier, from about 0.01% to 4%; the combination of emulsifiers to make up that percentage; the temperature and time as mentioned in previous section. These sweeteners provide a flexible, controllable, low-dose Cannabis experience, delivered in an understandable and desirable form. They can be used in beverages, such as coffee or tea.
- The invention sweeteners assure that the THC is both fast acting and highly metabolizable. It assures that the consumer experiences a consistent experience from ingesting the product, instead of having a wide variation of experiences, including how long it takes to take effect, and how the effect will be each time.
- The extracts of the invention can be mixed with other ingredients such as soda and other like liquids.
- The process for making the Cannabis infused elixirs of the invention is as follows. The elixirs are essentially syrups, fruit syrups, and various flavored and unflavored syrups. The ingredients to make a batch of the invention elixirs include an emulsifying agent in the amount of about 0.12 to about 2%. A gallon of fruit syrup; flavored or unflavored and Cannabis oil in the amount between about 1000-2000 mg.
- The syrup is heated to about 120-220 degrees F. The Cannabis oil is added to this heated mixture and blended in a rotor for about 1 to 7 minutes, during which time the emulsifier is added in. Each serving size has about 3 to 20 mg per ounce of water-soluble Cannabis oil.
- Other variations include various doses of Cannabis oil in the range of about 5 to 30 mg and different flavor profiles including lime, pomegranate, orange, lemon and others; and different serving sizes between about 1 and about 64 oz.
- The disclosure is further described with the help of the following examples. These examples, however, should not be construed to limit the scope of the disclosure.
- A Cannabis infused chocolate is provided that is bioavailable and delivers fast acting effects of the Cannabis when ingested. The method of making such includes use of about 5 to 10 oz of a base oil of either vegetable glycerine or coconut oil. A high quality liquor such as cognac or whiskey can be added but is optional. The base oil liquid is heated to between about 120 to 220° F. The Cannabis oil extract is added equal to about 110 to 1120 mg THC. The emulsifiers are added next, generally in the following amounts: about 0.5% lecithin, 0.15% xanthan gum, about 0.1% cyclodextrin. The emulsifiers can be used individually or in combination. The hot mixture is blended in a high speed blender or other machine, run on high speed for about 2 minutes. The mixture is allowed to cool to room temperature.
- After the mixture has cooled, about 10 lb of melted chocolate is added and allowed to temper before depositing in a mold, then cooling to about 55° F.
- Several experiments were run using several different emulsifiers and combinations of different coconut oils: solid and liquid (MCT). (Note: liquid MCT is coconut oil that has medium chain triglyceride). Guar gum, lecithin, and cyclodextrin were tested as emulsifying agents and provided good results. However, xanthan gum was the most effective and provided the best emulsification of the oil and water, at the lowest viscosity.
- The emulsification process that was determined the best had the added effect of making the THC more bioavailable by making the oleo molecule water-soluble. This had another added effect of making it fast acting, taking effect in as little as about 15 minutes.
- The method used to produce the invention emulsifications, included first heating extra virgin organic coconut oil to between about 120 to about 220 degrees F. CO2 extracted Cannabis oil is added. In a high speed blender (or similar machine) coconut water is added to the coconut fat (oil) to ensure emulsification. While blending, xanthan gum powder is added in an amount between about 0.15% and about 0.45% of the total volume of finished product. Percentages used herein are on a dry weight basis and are based on the total volume of the finished product. The blender is run at high speed for between 30 seconds and 2. The resulting emulsification is used to produce a variety of Cannabis infused products. The invention process makes the THC more bioavailable by making the oleo molecule water-soluble. Thus, upon ingestion, making it fast acting, taking effect in as little as 15 minutes.
- A variety of Cannabis infused products were prepared and tested in a random study group of 40 individuals. The products tested included Cannabis infused sugar, a cannabinoid/caffeine emulsification and a Cannabis infused elixir and are summarized in the tables below.
- Each of the 40 individuals tested one of the products from Tables 2, 3 and 4. The breakdown of products tested was 10% (4 people) of the cannabinoid/caffeine emulsification; 20% (8 people) of cannabinoid elixirs and 70% (28 people) of the Cannabis infused sugar.
-
TABLE 2 Cannabis infused sugar (Serving size 1 tsp) Sugar Product #1 #2 #3 #4 #5* Cannabis Oil (mg/tsp) 20 40 20 40 40 Sugar (lbs) 5 3 10 3 Alcohol (oz) 20 12 40 12 6 Lecithin (%)** 2 2 2 1 0 Cyclodextrin (%)** 0 0 0.03 0.12 0.25 *The sugar used in this sample was maple sugar. **% of final product. -
TABLE 3 Cannabinoid/caffeine emulsification (Serving size 2 oz) Amount in Component emulsification THC (per serving) 10 mg Coconut Fat (SOLID) 2.75% MCT 0.65% Coconut Water 96% Cyclodextrin 0.12% Xanthan Gum 0.12% Caffeine 1000 mg * Lime and coconut extract were added for flavor -
TABLE 4 Cannabinoid elixirs (flavored syrups) (Serving size 1 oz) Amount in Component emulsification THC 10 mg/oz Flavored syrup 99.64% Cyclodextrin 0.16% Xanthan Gum 0.12% Cannabis Oil 0.04% - Participants in the study were asked a series of questions, the results of which are summarized in the tables below. Q1. How long until you experienced an initial onset of effect after ingestion? The results are in Table 5. In all three products tested the onset of the Cannabis effects were less than 15-20 min.
-
TABLE 5 Results for Onset of Effect Time >10 10-15 15-20 20-30 30-40 <40 min min min min min min Sugar 10.71% 28.57% 32% 7.14% 7.14% 14.29% Emulsification 0 50% 50% 0 0 0 Elixir 12.4% 25% 25% 25% 12.5% 0 - Q2. On a scale of 1 to 5, the participants were asked to describe the strength of the initial onset experience after ingestion. A majority of respondents said the effects were mild to moderate. The results are in Table 6.
-
TABLE 6 Results for Strength Time 1 No effect 2 Very Mild 3 Mild 4 Moderate 5 Strong Sugar 3.57% 3.57% 39.29% 46.43% 7.14% Emulsification 0 0 50% 50% 0 Elixir 0 25% 50% 12.5% 12.5% - Q3. Compared to other Cannabis edibles, the participants were asked how they would characterize the rapidity of the onset of the products they tested. The respondents were comparing the invention products to other products they ingested including gummy bears, brownies and baked goods containing Cannabis. The results are in Table 7.
-
TABLE 7 Results for Comparison to Other Cannabis Edibles 1 Much 2 Somewhat 3 No 4 Somewhat 5 Much Time Slower slower difference faster Faster Sugar 3.85% 3.85% 0 34.62% 57.69% Emulsification 0 0 0 75% 25% Elixir 0 0 0 25% 75% - In sum, in all embodiments, i.e. the Cannabis infused sugar, emulsification and elixir 92.7% to 100% said that the invention products acted faster than other Cannabis edibles.
- The water-soluble cannabinoid composition and caffeine emulsifications of the invention provide a beneficial experience for people experiencing a variety of ailments: insomnia, muscle aches, anxiety, etc, or are in recovery from surgery, or in chemotherapy. The emulsifications make the Cannabis oil molecules hydrophilic, and thus water-soluble, which makes the THC bioavailable, faster acting, and more highly metabolizable.
- Medical marijuana patients are often challenged by the mediums they are offered for consuming Cannabis. The water-soluble Cannabis of the invention provides them a convenient, and smokeless, alternative to access the cannabinoids they need to alleviate their ailments.
- The foregoing description of various and preferred embodiments of the present invention has been provided for purposes of illustration only, and it is understood that numerous modifications, variations and alterations may be made without departing from the scope and spirit of the invention as set forth in the claims. The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
- Note that in the specification and claims, “about” or “approximately” means within twenty percent (20%) of the numerical amount cited.
- Although the invention has been described in detail with particular reference to these embodiments, other embodiments can achieve the same results. Variations and modifications of the present invention will be obvious to those skilled in the art and it is intended to cover in the appended claims all such modifications and equivalents. The entire disclosures of all references, applications, patents, and publications cited above are hereby incorporated by reference.
Claims (42)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/854,800 US20220087972A9 (en) | 2016-04-15 | 2020-04-21 | Cannabinoid Compositions |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662323154P | 2016-04-15 | 2016-04-15 | |
US201662328975P | 2016-04-28 | 2016-04-28 | |
PCT/US2017/027550 WO2017180954A1 (en) | 2016-04-15 | 2017-04-14 | Method of making cannabis oil hydrophiilic using emulsifiers and related cannabinoid compositions |
PCT/US2017/027549 WO2017180953A1 (en) | 2016-04-15 | 2017-04-14 | Cannabis infused sweeteners and elixirs |
PCT/US2017/027543 WO2017180948A1 (en) | 2016-04-15 | 2017-04-14 | Cannabinoid and caffeine emulsifications |
US16/161,027 US10624844B2 (en) | 2016-04-15 | 2018-10-15 | Cannabinoid compositions comprising cannabis oil and methods of making thereof |
US16/854,800 US20220087972A9 (en) | 2016-04-15 | 2020-04-21 | Cannabinoid Compositions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/161,027 Continuation-In-Part US10624844B2 (en) | 2016-04-15 | 2018-10-15 | Cannabinoid compositions comprising cannabis oil and methods of making thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
US20200316014A1 US20200316014A1 (en) | 2020-10-08 |
US20220087972A9 true US20220087972A9 (en) | 2022-03-24 |
Family
ID=72663676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/854,800 Abandoned US20220087972A9 (en) | 2016-04-15 | 2020-04-21 | Cannabinoid Compositions |
Country Status (1)
Country | Link |
---|---|
US (1) | US20220087972A9 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104544069A (en) * | 2014-12-31 | 2015-04-29 | 无限极(中国)有限公司 | Preparation method for hemp seed oil microcapsules |
US20160324776A1 (en) * | 2014-05-12 | 2016-11-10 | HDDC Holdings, LLC | Cannabinoid caffeinated drinks, powder, beans, and cannabinoid loose tea leaf |
-
2020
- 2020-04-21 US US16/854,800 patent/US20220087972A9/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160324776A1 (en) * | 2014-05-12 | 2016-11-10 | HDDC Holdings, LLC | Cannabinoid caffeinated drinks, powder, beans, and cannabinoid loose tea leaf |
CN104544069A (en) * | 2014-12-31 | 2015-04-29 | 无限极(中国)有限公司 | Preparation method for hemp seed oil microcapsules |
Also Published As
Publication number | Publication date |
---|---|
US20200316014A1 (en) | 2020-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10624844B2 (en) | Cannabinoid compositions comprising cannabis oil and methods of making thereof | |
US10617636B2 (en) | Cannabis infused sweeteners and elixirs | |
JP2019511579A5 (en) | ||
US20180200315A1 (en) | Cannabinoid and caffeine emulsifications | |
US20200170950A1 (en) | Compositions comprising a cannabinoid or a cannabis-derived compound, methods of making and use | |
CN101720965A (en) | MCC/hydrocolloid stabilizers and edible compositions comprising the same | |
AU747611B2 (en) | Novel chitosan-containing liquid compositions and methods for their preparation and use | |
CN103842425A (en) | Stabilizer composition of microcrystalline cellulose and carboxymethylcellulose, method for making, and uses | |
US20060105021A1 (en) | Cholesterol-reducing liquid | |
CN100584218C (en) | MCC/hydrocolloid stabilizers and edible compositions comprising the same | |
US10299493B2 (en) | Dietary supplement compositions with enhanced delivery matrix, gummies, chocolates, atomizers and powders containing same, and methods of making same | |
JP6615750B2 (en) | Rich liquid food | |
JP6569642B2 (en) | Internal liquid | |
US20200316014A1 (en) | Cannabinoid Compositions | |
JP2004514765A (en) | Beverage emulsion stabilizer | |
CN115886138A (en) | Animal oral fish oil microemulsion and preparation method thereof | |
RU2734830C1 (en) | Composition for production of alcohol-free emulsion beverage | |
JP2002212201A (en) | Polysaccharide extracted from seaweed, and process for preparation and use thereof | |
JP2006191904A (en) | Gelling agent preparation | |
US20210401733A1 (en) | Skin crème | |
KR20200088762A (en) | Method for producing red ginseng ball loaded with effective component and red ginseng ball loaded with effective component produced by the same method | |
JP2006193662A (en) | Additive for thickening composition | |
MXPA06011484A (en) | Mcc/hydrocolloid stabilizers and edible compositions comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
AS | Assignment |
Owner name: SRE WELLNESS, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SILVER, RONALD;REEL/FRAME:053528/0735 Effective date: 20200818 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |